Long	O
-	O
Term	O
Factors	O
Associated	O
With	O
Falls	O
and	O
Fractures	O
Poststroke	O

Edited	O
by	O
:	O
Yannick	O
Béjot	O
,	O
Centre	O
Hospitalier	O
Regional	O
Universitaire	O
De	O
Dijon	O
,	O
France	O

Reviewed	O
by	O
:	O
Christian	O
H	O
.	O

Nolte	O
,	O
Charité	O
Universitätsmedizin	O
Berlin	O
,	O
Germany	O
;	O
Loes	O
C	O
.	O

A	O
.	O

Rutten	O
-	O
Jacobs	O
,	O
University	O
of	O
Cambridge	O
,	O
United	O
Kingdom	O

Specialty	O
section	O
:	O
This	O
article	O
was	O
submitted	O
to	O
Stroke	B-DS
,	O
a	O
section	O
of	O
the	O
journal	O
Frontiers	O
in	O
Neurology	O

Background	O

Risk	O
factors	O
for	O
poststroke	O
falls	O
and	O
fractures	O
remain	O
poorly	O
understood	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
which	O
factors	O
increased	O
risk	O
of	O
these	O
events	O
after	O
stroke	B-DS
.	O

Methods	O

Data	O
from	O
7	O
,	O
267	O
hospitalized	O
stroke	B-DS
patients	O
were	O
acquired	O
from	O
the	O
Norfolk	O
and	O
Norwich	O
University	O
Hospital	O
Stroke	B-DS
Register	O
from	O
2003	O
–	O
2015	O
.	O

The	O
impacts	O
of	O
multiple	O
patient	O
level	O
and	O
stroke	B-DS
characteristics	O
and	O
comorbidities	O
on	O
post	O
-	O
discharge	O
falls	O
and	O
fractures	O
were	O
assessed	O
.	O

Univariate	O
and	O
multivariable	O
models	O
were	O
constructed	O
,	O
adjusting	O
for	O
multiple	O
confounders	O
,	O
using	O
binary	O
logistic	O
regression	O
for	O
short	O
-	O
term	O
analysis	O
(	O
up	O
to	O
1	O
-	O
year	O
post	O
-	O
discharge	O
)	O
and	O
Cox	O
-	O
proportional	O
hazard	O
models	O
for	O
longer	O
term	O
analysis	O
(	O
1	O
–	O
3	O
,	O
3	O
–	O
5	O
,	O
and	O
0	O
–	O
10	O
years	O
follow	O
-	O
up	O
).	O

Results	O

The	O
mean	O
age	O
(	O
SD	O
)	O
was	O
76	O
.	O
3	O
±	O
12	O
.	O
1	O
years	O
at	O
baseline	O
.	O

1	O
,	O
138	O
(	O
15	O
.	O
7	O
%)	O
participants	O
had	O
an	O
incident	O
fall	O
;	O
and	O
666	O
(	O
9	O
.	O
2	O
%)	O
an	O
incident	O
fracture	O
during	O
the	O
10	O
-	O
year	O
follow	O
-	O
up	O
(	O
total	O
person	O
years	O
=	O
64	O
,	O
447	O
.	O
99	O
for	O
falls	O
and	O
67	O
,	O
726	O
.	O
70	O
for	O
fractures	O
).	O

Half	O
of	O
the	O
sample	O
population	O
were	O
females	O
(	O
50	O
.	O
6	O
%)	O
and	O
the	O
majority	O
had	O
an	O
ischemic	B-DS
stroke	I-DS
(	O
89	O
.	O
8	O
%).	O

After	O
adjusting	O
for	O
confounders	O
:	O
age	O
,	O
sex	O
,	O
previous	O
history	O
of	O
falls	O
,	O
and	O
atrial	B-DS
fibrillation	I-DS
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
both	O
falls	O
and	O
fractures	O
during	O
follow	O
-	O
up	O
.	O

Furthermore	O
,	O
chronic	B-DS
kidney	I-DS
disease	I-DS
and	O
hyperlipidemia	B-DS
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
falls	O
,	O
while	O
previous	O
stroke	B-DS
/	O
transient	B-DS
ischemic	I-DS
attack	I-DS
increased	O
fracture	O
risk	O
.	O

Total	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS
and	O
a	O
prestroke	O
modified	O
Rankin	O
Scale	O
score	O
of	O
3	O
–	O
5	O
were	O
associated	O
with	O
decreased	O
risk	O
of	O
both	O
events	O
,	O
with	O
hypertension	B-DS
and	O
cancer	B-DS
decreasing	O
risk	O
of	O
falls	O
only	O
.	O

Conclusion	O

We	O
identified	O
demographic	O
,	O
stroke	B-DS
-	O
related	O
,	O
and	O
comorbid	O
factors	O
associated	O
with	O
poststroke	O
falls	O
and	O
fracture	O
incidence	O
.	O

Further	O
studies	O
are	O
required	O
to	O
examine	O
and	O
establish	O
the	O
relationship	O
between	O
reversible	O
factors	O
and	O
further	O
explore	O
the	O
role	O
of	O
preventative	O
measures	O
to	O
prevent	O
poststroke	O
falls	O
and	O
fractures	O
.	O

Introduction	O

Functional	O
decline	O
subsequent	O
to	O
acute	B-DS
stroke	I-DS
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
falls	O
(	O
1	O
–	O
5	O
)	O
and	O
reduction	O
in	O
bone	O
mineral	O
density	O
after	O
stroke	B-DS
has	O
been	O
well	O
documented	O
as	O
a	O
risk	O
factor	O
for	O
fractures	O
(	O
6	O
–	O
8	O
).	O

Falls	O
and	O
fractures	O
are	O
major	O
causes	O
of	O
functional	O
decline	O
,	O
poor	O
quality	O
of	O
life	O
,	O
frailty	O
,	O
dependency	O
,	O
and	O
mortality	O
.	O

It	O
is	O
,	O
therefore	O
,	O
important	O
to	O
better	O
understand	O
the	O
risk	O
factors	O
for	O
poststroke	O
falls	O
and	O
fractures	O
to	O
develop	O
intervention	O
strategies	O
,	O
which	O
can	O
have	O
substantial	O
health	O
benefit	O
.	O

However	O
,	O
previous	O
studies	O
assessing	O
such	O
risk	O
factors	O
have	O
several	O
limitations	O
.	O

First	O
,	O
risk	O
factor	O
studies	O
for	O
falls	O
have	O
only	O
been	O
conducted	O
over	O
the	O
short	O
-	O
term	O
—	O
such	O
as	O
the	O
1	O
and	O
6	O
month	O
analyses	O
conducted	O
by	O
Kerse	O
et	O
al	O
.	O
(	O
9	O
).	O

Second	O
,	O
limited	O
comorbidity	O
adjustment	O
has	O
been	O
an	O
important	O
limitation	O
in	O
previous	O
studies	O
;	O
Lin	O
et	O
al	O
.	O
in	O
their	O
assessment	O
of	O
hip	O
fracture	O
after	O
stroke	B-DS
,	O
adjusted	O
for	O
relatively	O
few	O
variables	O
(	O
10	O
)—	O
including	O
only	O
six	O
comorbidities	O
(	O
hypertension	B-DS
,	O
diabetes	B-DS
,	O
parkinsonism	B-DS
,	O
epilepsy	B-DS
,	O
dementia	B-DS
,	O
and	O
depression	B-DS
),	O
age	O
,	O
sex	O
,	O
stroke	B-DS
type	O
,	O
and	O
five	O
categories	O
of	O
medication	O
,	O
therefore	O
,	O
omitting	O
potentially	O
important	O
factors	O
and	O
resulting	O
in	O
increased	O
risk	O
of	O
confounding	O
.	O

Third	O
,	O
small	O
sample	O
sizes	O
resulted	O
in	O
limited	O
statistical	O
power	O
,	O
for	O
example	O
,	O
Mackintosh	O
et	O
al	O
.	O
(	O
11	O
),	O
including	O
only	O
55	O
patients	O
in	O
their	O
final	O
analyses	O
,	O
as	O
a	O
more	O
extreme	O
example	O
.	O

Finally	O
,	O
previous	O
studies	O
have	O
focused	O
on	O
investigating	O
fall	O
risk	O
in	O
relation	O
to	O
physical	O
assessments	O
,	O
such	O
as	O
the	O
Berg	O
-	O
Balance	O
Scale	O
or	O
Timed	O
Up	O
and	O
Go	O
tests	O
,	O
which	O
require	O
additional	O
time	O
and	O
resources	O
to	O
be	O
applied	O
in	O
the	O
clinical	O
setting	O
and	O
are	O
also	O
perhaps	O
irrelevant	O
to	O
the	O
majority	O
of	O
stroke	B-DS
patients	O
with	O
significant	O
disabilities	O
(	O
3	O
,	O
11	O
–	O
16	O
).	O

The	O
current	O
study	O
,	O
therefore	O
,	O
aimed	O
to	O
evaluate	O
the	O
association	O
of	O
a	O
variety	O
of	O
potential	O
risk	O
factors	O
,	O
including	O
demographic	O
variables	O
,	O
stroke	B-DS
-	O
related	O
factors	O
,	O
and	O
comorbidities	O
,	O
and	O
falls	O
and	O
fracture	O
risk	O
over	O
the	O
long	O
-	O
term	O
using	O
a	O
large	O
,	O
prospectively	O
collected	O
dataset	O
with	O
consecutive	O
stroke	B-DS
admissions	O
controlling	O
for	O
multiple	O
confounders	O
.	O

An	O
association	O
between	O
these	O
factors	O
and	O
an	O
increased	O
risk	O
of	O
falls	O
and	O
fractures	O
may	O
facilitate	O
the	O
provision	O
of	O
prognostic	O
information	O
on	O
the	O
important	O
long	O
-	O
term	O
sequelae	O
of	O
stroke	B-DS
as	O
well	O
as	O
aid	O
the	O
implementation	O
of	O
targeted	O
preventive	O
strategies	O
to	O
improve	O
acute	B-DS
stroke	I-DS
outcomes	O
.	O

Materials	O
and	O
Methods	O

The	O
study	O
population	O
was	O
drawn	O
from	O
the	O
Norfolk	O
and	O
Norwich	O
University	O
Hospital	O
(	O
NNUH	O
)	O
Stroke	B-DS
Register	O
and	O
included	O
all	O
consecutive	O
stroke	B-DS
admissions	O
from	O
January	O
2003	O
to	O
April	O
2015	O
.	O

NNUH	O
is	O
a	O
regional	O
tertiary	O
hospital	O
with	O
a	O
catchment	O
population	O
of	O
approximately	O
750	O
,	O
000	O
people	O
in	O
the	O
Norfolk	O
(	O
East	O
Anglia	O
)	O
Region	O
,	O
UK	O
.	O

Record	O
linkage	O
enabled	O
the	O
ascertainment	O
of	O
comorbidity	O
and	O
mortality	O
data	O
,	O
over	O
a	O
long	O
term	O
follow	O
-	O
up	O
.	O

The	O
register	O
received	O
research	O
database	O
ethical	O
approval	O
from	O
the	O
Newcastle	O
and	O
Tyneside	O
National	O
Health	O
Service	O
and	O
Research	O
Ethics	O
Committee	O
(	O
12	O
/	O
NE	O
/	O
0170	O
),	O
with	O
the	O
study	O
protocol	O
being	O
approved	O
by	O
the	O
Steering	O
Committee	O
of	O
the	O
Register	O
.	O

The	O
data	O
collection	O
methods	O
have	O
previously	O
been	O
described	O
(	O
17	O
).	O

Supervised	O
by	O
stroke	B-DS
specialists	O
,	O
the	O
data	O
entry	O
team	O
transferred	O
paper	O
and	O
electronic	O
records	O
onto	O
the	O
stroke	B-DS
register	O
database	O
prospectively	O
.	O

Patients	O
were	O
included	O
if	O
a	O
diagnosis	O
of	O
acute	B-DS
stroke	I-DS
had	O
been	O
confirmed	O
by	O
a	O
combination	O
of	O
clinical	O
examination	O
,	O
medical	O
history	O
,	O
and	O
neuroimaging	O
.	O

The	O
prestroke	O
modified	O
Rankin	O
Scale	O
(	O
mRS	O
)	O
score	O
was	O
confirmed	O
from	O
medical	O
records	O
.	O

Follow	O
-	O
up	O
for	O
mortality	O
data	O
was	O
obtained	O
by	O
electronic	O
record	O
linkage	O
with	O
the	O
Office	O
of	O
National	O
Statistics	O
data	O
.	O

The	O
predictor	O
variables	O
of	O
interest	O
in	O
this	O
study	O
were	O
;	O
age	O
,	O
sex	O
,	O
stroke	B-DS
type	O
(	O
ischemic	O
or	O
hemorrhagic	O
),	O
Oxfordshire	O
Community	O
Stroke	B-DS
Project	O
(	O
OCSP	O
)	O
classification	O
,	O
prestroke	O
mRS	O
score	O
,	O
previous	O
fall	O
,	O
fracture	O
,	O
stroke	B-DS
or	O
transient	B-DS
ischemic	I-DS
attack	I-DS
(	O
TIA	B-DS
),	O
congestive	B-DS
heart	I-DS
failure	I-DS
,	O
coronary	B-DS
heart	I-DS
disease	I-DS
or	O
myocardial	B-DS
infarction	I-DS
,	O
atrial	B-DS
fibrillation	I-DS
,	O
diabetes	B-DS
,	O
hypertension	B-DS
,	O
peripheral	B-DS
vascular	I-DS
disease	I-DS
,	O
chronic	B-DS
kidney	I-DS
disease	I-DS
,	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
,	O
dementia	B-DS
,	O
hyperlipidemia	B-DS
,	O
and	O
cancer	B-DS
.	O

The	O
outcomes	O
of	O
interest	O
were	O
first	O
incident	O
fall	O
and	O
fracture	O
after	O
hospital	O
discharge	O
from	O
the	O
index	O
stroke	B-DS
episode	O
occurring	O
over	O
the	O
follow	O
-	O
up	O
period	O
.	O

International	O
Classification	O
of	O
Diseases	O
(	O
ICD	O
-	O
10	O
)	O
codes	O
included	O
for	O
falls	O
were	O
W00	O
to	O
W19	O
and	O
the	O
codes	O
included	O
for	O
fractures	O
were	O
S82	O
,	O
S72	O
,	O
S62	O
,	O
S52	O
,	O
S42	O
,	O
S32	O
,	O
S22	O
,	O
S12	O
,	O
S02	O
,	O
T14	O
.	O
2	O
,	O
and	O
T10	O
.	O

Statistical	O
Analysis	O

Statistical	O
analysis	O
was	O
performed	O
using	O
SPSS	O
Statistics	O
(	O
version	O
24	O
,	O
IBM	O
Corp	O
.,	O
Armonk	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
).	O

Descriptive	O
statistics	O
were	O
calculated	O
separately	O
for	O
those	O
who	O
had	O
a	O
fall	O
or	O
a	O
fracture	O
after	O
stroke	B-DS
with	O
categorical	O
variables	O
presented	O
as	O
the	O
number	O
and	O
given	O
percentage	O
and	O
continuous	O
variables	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
.	O

The	O
association	O
between	O
falls	O
and	O
fractures	O
and	O
the	O
risk	O
factors	O
under	O
evaluation	O
were	O
assessed	O
using	O
the	O
chi	O
-	O
squared	O
and	O
t	O
-	O
tests	O
for	O
categorical	O
and	O
continuous	O
data	O
,	O
respectively	O
.	O

Univariate	O
and	O
multivariable	O
models	O
were	O
constructed	O
to	O
calculate	O
unadjusted	O
and	O
adjusted	O
odds	O
ratios	O
from	O
0	O
to	O
365	O
days	O
(	O
0	O
–	O
1	O
year	O
,	O
short	O
term	O
)	O
using	O
binary	O
logistic	O
regression	O
,	O
and	O
hazard	O
ratios	O
from	O
366	O
to	O
1	O
,	O
095	O
days	O
(	O
1	O
–	O
3	O
years	O
,	O
medium	O
term	O
),	O
1	O
,	O
096	O
–	O
1	O
,	O
825	O
days	O
(	O
3	O
–	O
5	O
years	O
,	O
medium	O
-	O
long	O
term	O
),	O
and	O
the	O
full	O
follow	O
-	O
up	O
period	O
from	O
0	O
to	O
3	O
,	O
650	O
days	O
(	O
0	O
–	O
10	O
years	O
,	O
long	O
term	O
)	O
using	O
Cox	O
-	O
proportional	O
hazards	O
.	O

Univariate	O
analyses	O
were	O
conducted	O
by	O
individually	O
examining	O
the	O
association	O
of	O
each	O
factor	O
in	O
a	O
regression	O
model	O
alone	O
on	O
the	O
outcomes	O
of	O
post	O
-	O
discharge	O
falls	O
and	O
fractures	O
;	O
whereas	O
for	O
multivariable	O
analyses	O
,	O
all	O
variables	O
were	O
input	O
together	O
at	O
the	O
same	O
time	O
,	O
therefore	O
,	O
examining	O
their	O
combined	O
effect	O
on	O
the	O
outcomes	O
.	O

Results	O

A	O
total	O
of	O
11	O
,	O
729	O
stroke	B-DS
cases	O
were	O
recorded	O
between	O
January	O
2003	O
and	O
April	O
2015	O
.	O

Participants	O
were	O
excluded	O
if	O
they	O
did	O
not	O
meet	O
the	O
eligibility	O
criteria	O
for	O
the	O
study	O
,	O
leaving	O
a	O
total	O
of	O
7	O
,	O
267	O
people	O
(	O
Figure	O
S1	O
in	O
Supplementary	O
Material	O
).	O

The	O
mean	O
age	O
(	O
SD	O
)	O
of	O
the	O
study	O
population	O
at	O
baseline	O
was	O
76	O
.	O
3	O
±	O
12	O
.	O
1	O
years	O
and	O
50	O
.	O
6	O
%	O
(	O
3	O
,	O
678	O
)	O
were	O
females	O
.	O

Ischemic	B-DS
stroke	I-DS
occurred	O
in	O
89	O
.	O
8	O
%	O
of	O
cases	O
,	O
while	O
the	O
most	O
common	O
OCSP	O
stroke	B-DS
classification	O
was	O
partial	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS
(	O
PACS	B-DS
)	O
(	O
37	O
.	O
8	O
%).	O

The	O
majority	O
of	O
patients	O
were	O
completely	O
independent	O
before	O
their	O
stroke	B-DS
with	O
a	O
prestroke	O
mRS	O
score	O
of	O
0	O
(	O
67	O
.	O
5	O
%).	O

1	O
,	O
138	O
(	O
15	O
.	O
7	O
%)	O
of	O
patients	O
suffered	O
incident	O
falls	O
and	O
666	O
(	O
9	O
.	O
2	O
%)	O
had	O
an	O
incident	O
fracture	O
post	O
-	O
discharge	O
.	O

Approximately	O
two	O
-	O
thirds	O
of	O
both	O
falls	O
and	O
fractures	O
occurred	O
in	O
women	B-OG
(	O
60	O
.	O
7	O
and	O
65	O
.	O
0	O
%,	O
respectively	O
).	O

Table	O
1	O
shows	O
the	O
baseline	O
characteristics	O
for	O
patients	O
who	O
had	O
a	O
post	O
-	O
discharge	O
fall	O
or	O
fracture	O
after	O
stroke	B-DS
compared	O
to	O
those	O
who	O
did	O
not	O
.	O

Both	O
falls	O
and	O
fractures	O
were	O
associated	O
with	O
increasing	O
age	O
(	O
P	O
<	O
0	O
.	O
001	O
);	O
45	O
.	O
1	O
%	O
of	O
falls	O
and	O
45	O
.	O
8	O
%	O
of	O
fractures	O
occurred	O
in	O
the	O
81	O
–	O
89	O
years	O
old	O
age	O
group	O
.	O

Regarding	O
OCSP	O
classification	O
,	O
falls	O
and	O
fractures	O
were	O
significantly	O
associated	O
with	O
less	O
severe	O
stroke	B-DS
,	O
as	O
most	O
events	O
occurred	O
in	O
the	O
lacunar	B-DS
stroke	I-DS
(	O
LACS	B-DS
)	O
or	O
PACS	B-DS
sub	O
-	O
types	O
(	O
30	O
.	O
8	O
and	O
41	O
.	O
0	O
%	O
for	O
falls	O
and	O
30	O
.	O
5	O
and	O
40	O
.	O
2	O
%	O
for	O
fractures	O
,	O
respectively	O
).	O

Both	O
events	O
were	O
associated	O
with	O
a	O
low	O
prestroke	O
mRS	O
score	O
,	O
with	O
over	O
60	O
%	O
of	O
falls	O
and	O
fractures	O
being	O
found	O
in	O
those	O
with	O
a	O
score	O
of	O
0	O
.	O

A	O
history	O
of	O
falls	O
and	O
fractures	O
were	O
both	O
associated	O
with	O
increased	O
incidence	O
of	O
post	O
-	O
discharge	O
falls	O
and	O
fractures	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
addition	O
,	O
previous	O
stroke	B-DS
/	O
TIA	B-DS
and	O
hypertension	B-DS
were	O
associated	O
with	O
fractures	O
and	O
atrial	B-DS
fibrillation	I-DS
was	O
associated	O
with	O
both	O
falls	O
and	O
fractures	O
.	O

Characteristics	O
of	O
patients	O
with	O
and	O
without	O
post	O
-	O
discharge	O
falls	O
and	O
fractures	O
.	O

Fall	O

P	O

Fracture	O

P	O

No	O
(%)	O

Yes	O
(%)	O

No	O
(%)	O

Yes	O
(%)	O

Agea	O

75	O
.	O
48	O
(±	O
12	O
.	O
47	O
)	O

80	O
.	O
44	O
(±	O
9	O
.	O
20	O
)	O

<	O
0	O
.	O
001	O

75	O
.	O
88	O
(±	O
12	O
.	O
30	O
)	O

80	O
.	O
07	O
(±	O
9	O
.	O
72	O
)	O

<	O
0	O
.	O
001	O

Age	O
group	O

<	O
65	O

1	O
,	O
111	O
(	O
18	O
.	O
1	O
)	O

71	O
(	O
6	O
.	O
2	O
)	O

<	O
0	O
.	O
001	O

1	O
,	O
127	O
(	O
17	O
.	O
1	O
)	O

55	O
(	O
8	O
.	O
3	O
)	O

<	O
0	O
.	O
001	O

65	O
–	O
70	O

718	O
(	O
11	O
.	O
7	O
)	O

78	O
(	O
6	O
.	O
9	O
)	O

755	O
(	O
11	O
.	O
4	O
)	O

41	O
(	O
6	O
.	O
2	O
)	O

71	O
–	O
80	O

1	O
,	O
831	O
(	O
29	O
.	O
9	O
)	O

331	O
(	O
29	O
.	O
1	O
)	O

1	O
,	O
978	O
(	O
30	O
.	O
0	O
)	O

184	O
(	O
27	O
.	O
6	O
)	O

81	O
–	O
89	O

1	O
,	O
893	O
(	O
30	O
.	O
9	O
)	O

513	O
(	O
45	O
.	O
1	O
)	O

2	O
,	O
101	O
(	O
31	O
.	O
8	O
)	O

305	O
(	O
45	O
.	O
8	O
)	O

90	O
+	O

576	O
(	O
9	O
.	O
4	O
)	O

145	O
(	O
12	O
.	O
7	O
)	O

640	O
(	O
9	O
.	O
7	O
)	O

81	O
(	O
12	O
.	O
2	O
)	O


Sex	O

Women	B-OG

2	O
,	O
987	O
(	O
48	O
.	O
7	O
)	O

691	O
(	O
60	O
.	O
7	O
)	O

<	O
0	O
.	O
001	O

3	O
,	O
245	O
(	O
49	O
.	O
2	O
)	O

433	O
(	O
65	O
.	O
0	O
)	O

<	O
0	O
.	O
001	O

Men	O

3	O
,	O
142	O
(	O
51	O
.	O
3	O
)	O

447	O
(	O
39	O
.	O
3	O
)	O

3	O
,	O
356	O
(	O
50	O
.	O
8	O
)	O

233	O
(	O
35	O
.	O
0	O
)	O


Type	O
of	O
stroke	B-DS

Infarct	O

5	O
,	O
495	O
(	O
89	O
.	O
7	O
)	O

1	O
,	O
028	O
(	O
90	O
.	O
3	O
)	O

0	O
.	O
522	O

5	O
,	O
921	O
(	O
89	O
.	O
7	O
)	O

602	O
(	O
90	O
.	O
4	O
)	O

0	O
.	O
621	O

Hemorrhage	O

634	O
(	O
10	O
.	O
3	O
)	O

110	O
(	O
9	O
.	O
7	O
)	O

680	O
(	O
10	O
.	O
3	O
)	O

64	O
(	O
9	O
.	O
6	O
)	O


Oxfordshire	O
community	O
stroke	B-DS
project	O
classification	O

Lacunar	B-DS
stroke	I-DS

1	O
,	O
665	O
(	O
27	O
.	O
2	O
)	O

350	O
(	O
30	O
.	O
8	O
)	O

<	O
0	O
.	O
001	O

1	O
,	O
812	O
(	O
27	O
.	O
5	O
)	O

203	O
(	O
30	O
.	O
5	O
)	O

0	O
.	O
007	O

Partial	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

2	O
,	O
282	O
(	O
37	O
.	O
2	O
)	O

467	O
(	O
41	O
.	O
0	O
)	O

2	O
,	O
481	O
(	O
37	O
.	O
6	O
)	O

268	O
(	O
40	O
.	O
2	O
)	O

Posterior	B-DS
circulation	I-DS
stroke	I-DS

1	O
,	O
127	O
(	O
18	O
.	O
4	O
)	O

182	O
(	O
16	O
.	O
0	O
)	O

1	O
,	O
199	O
(	O
18	O
.	O
2	O
)	O

110	O
(	O
16	O
.	O
5	O
)	O

Total	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

840	O
(	O
13	O
.	O
7	O
)	O

102	O
(	O
9	O
.	O
0	O
)	O

883	O
(	O
13	O
.	O
4	O
)	O

59	O
(	O
8	O
.	O
9	O
)	O

Undetermined	O

215	O
(	O
3	O
.	O
5	O
)	O

37	O
(	O
3	O
.	O
3	O
)	O

226	O
(	O
3	O
.	O
4	O
)	O

26	O
(	O
3	O
.	O
9	O
)	O


Prestroke	O
modified	O
Rankin	O
score	O

0	O

4	O
,	O
200	O
(	O
68	O
.	O
5	O
)	O

708	O
(	O
62	O
.	O
2	O
)	O

<	O
0	O
.	O
001	O

4	O
,	O
488	O
(	O
68	O
.	O
0	O
)	O

420	O
(	O
63	O
.	O
1	O
)	O

0	O
.	O
027	O

1	O
–	O
2	O

1	O
,	O
138	O
(	O
18	O
.	O
6	O
)	O

263	O
(	O
23	O
.	O
1	O
)	O

1	O
,	O
250	O
(	O
18	O
.	O
9	O
)	O

151	O
(	O
22	O
.	O
7	O
)	O

3	O
–	O
5	O

791	O
(	O
12	O
.	O
9	O
)	O

167	O
(	O
14	O
.	O
7	O
)	O

863	O
(	O
13	O
.	O
1	O
)	O

95	O
(	O
14	O
.	O
3	O
)	O

Previous	O
fall	O

656	O
(	O
10	O
.	O
7	O
)	O

207	O
(	O
18	O
.	O
2	O
)	O

<	O
0	O
.	O
001	O

714	O
(	O
10	O
.	O
8	O
)	O

149	O
(	O
22	O
.	O
4	O
)	O

<	O
0	O
.	O
001	O

Previous	O
fracture	O

470	O
(	O
7	O
.	O
7	O
)	O

142	O
(	O
12	O
.	O
5	O
)	O

<	O
0	O
.	O
001	O

509	O
(	O
7	O
.	O
7	O
)	O

103	O
(	O
15	O
.	O
5	O
)	O

<	O
0	O
.	O
001	O


Comorbidities	O

Previous	O
stroke	B-DS
or	O
transient	B-DS
ischemic	I-DS
attack	I-DS

637	O
(	O
10	O
.	O
4	O
)	O

137	O
(	O
12	O
.	O
0	O
)	O

0	O
.	O
110	O

679	O
(	O
10	O
.	O
3	O
)	O

95	O
(	O
14	O
.	O
3	O
)	O

0	O
.	O
002	O

Congestive	B-DS
heart	I-DS
failure	I-DS

408	O
(	O
6	O
.	O
7	O
)	O

74	O
(	O
6	O
.	O
5	O
)	O

0	O
.	O
899	O

429	O
(	O
6	O
.	O
5	O
)	O

53	O
(	O
8	O
.	O
0	O
)	O

0	O
.	O
174	O

Coronary	B-DS
heart	I-DS
disease	I-DS
or	O
myocardial	B-DS
infarction	I-DS

953	O
(	O
15	O
.	O
5	O
)	O

193	O
(	O
17	O
.	O
0	O
)	O

0	O
.	O
248	O

1	O
,	O
026	O
(	O
15	O
.	O
5	O
)	O

120	O
(	O
18	O
.	O
0	O
)	O

0	O
.	O
106	O

Atrial	B-DS
fibrillation	I-DS

737	O
(	O
12	O
.	O
0	O
)	O

169	O
(	O
14	O
.	O
9	O
)	O

0	O
.	O
009	O

798	O
(	O
12	O
.	O
1	O
)	O

108	O
(	O
16	O
.	O
2	O
)	O

0	O
.	O
003	O

Diabetes	B-DS

564	O
(	O
9	O
.	O
2	O
)	O

109	O
(	O
9	O
.	O
6	O
)	O

0	O
.	O
729	O

607	O
(	O
9	O
.	O
2	O
)	O

66	O
(	O
9	O
.	O
9	O
)	O

0	O
.	O
592	O

Hypertension	B-DS

1	O
,	O
747	O
(	O
28	O
.	O
5	O
)	O

351	O
(	O
30	O
.	O
8	O
)	O

0	O
.	O
118	O

1	O
,	O
879	O
(	O
28	O
.	O
5	O
)	O

219	O
(	O
32	O
.	O
9	O
)	O

0	O
.	O
019	O

Peripheral	B-DS
vascular	I-DS
disease	I-DS

117	O
(	O
1	O
.	O
9	O
)	O

22	O
(	O
1	O
.	O
9	O
)	O

>	O
0	O
.	O
999	O

123	O
(	O
1	O
.	O
9	O
)	O

16	O
(	O
2	O
.	O
4	O
)	O

0	O
.	O
412	O

Chronic	B-DS
kidney	I-DS
disease	I-DS

160	O
(	O
2	O
.	O
6	O
)	O

36	O
(	O
3	O
.	O
2	O
)	O

0	O
.	O
338	O

175	O
(	O
2	O
.	O
7	O
)	O

21	O
(	O
3	O
.	O
2	O
)	O

0	O
.	O
524	O

Chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS

239	O
(	O
3	O
.	O
9	O
)	O

42	O
(	O
3	O
.	O
7	O
)	O

0	O
.	O
801	O

256	O
(	O
3	O
.	O
9	O
)	O

25	O
(	O
3	O
.	O
8	O
)	O

0	O
.	O
957	O

Dementia	B-DS

149	O
(	O
2	O
.	O
4	O
)	O

34	O
(	O
3	O
.	O
0	O
)	O

0	O
.	O
318	O

165	O
(	O
2	O
.	O
5	O
)	O

18	O
(	O
2	O
.	O
7	O
)	O

0	O
.	O
850	O

Hyperlipidemia	B-DS

240	O
(	O
3	O
.	O
9	O
)	O

55	O
(	O
4	O
.	O
8	O
)	O

0	O
.	O
174	O

265	O
(	O
4	O
.	O
0	O
)	O

30	O
(	O
4	O
.	O
5	O
)	O

0	O
.	O
612	O

Cancer	B-DS

655	O
(	O
10	O
.	O
7	O
)	O

103	O
(	O
9	O
.	O
1	O
)	O

0	O
.	O
108	O

692	O
(	O
10	O
.	O
5	O
)	O

66	O
(	O
9	O
.	O
9	O
)	O

0	O
.	O
693	O

aPresented	O
as	O
mean	O
(±	O
SD	O
).	O

Table	O
2	O
shows	O
the	O
results	O
of	O
the	O
univariate	O
analysis	O
for	O
risk	O
factors	O
for	O
poststroke	O
falls	O
after	O
discharge	O
over	O
the	O
prespecified	O
time	O
periods	O
.	O

The	O
total	O
many	O
factors	O
were	O
associated	O
with	O
post	O
-	O
discharge	O
fall	O
risk	O
in	O
these	O
unadjusted	O
analyses	O
,	O
with	O
the	O
risk	O
profile	O
changing	O
over	O
follow	O
-	O
up	O
.	O

Table	O
3	O
displays	O
the	O
results	O
of	O
the	O
fully	O
adjusted	O
multivariable	O
analysis	O
for	O
risk	O
factors	O
for	O
poststroke	O
falls	O
after	O
discharge	O
.	O

Increasing	O
age	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
falls	O
at	O
all	O
time	O
periods	O
.	O

Female	O
sex	O
and	O
a	O
history	O
of	O
falls	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
falls	O
at	O
three	O
of	O
the	O
time	O
periods	O
(	O
0	O
–	O
1	O
,	O
1	O
–	O
3	O
,	O
and	O
0	O
–	O
10	O
years	O
).	O

Total	B-DS
anterior	I-DS
circulation	I-DS
strokes	I-DS
(	O
TACS	B-DS
)	O
were	O
associated	O
with	O
reduced	O
risk	O
of	O
falls	O
from	O
3	O
to	O
5	O
years	O
and	O
over	O
the	O
whole	O
follow	O
-	O
up	O
.	O

A	O
prestroke	O
mRS	O
score	O
of	O
3	O
–	O
5	O
(	O
indicating	O
moderate	O
–	O
severe	O
disability	O
)	O
was	O
also	O
associated	O
with	O
reduced	O
risk	O
of	O
falls	O
over	O
the	O
whole	O
follow	O
-	O
up	O
period	O
of	O
0	O
–	O
10	O
years	O
.	O

Chronic	B-DS
kidney	I-DS
disease	I-DS
was	O
associated	O
with	O
an	O
increased	O
falls	O
risk	O
at	O
0	O
–	O
1	O
year	O
and	O
atrial	B-DS
fibrillation	I-DS
at	O
1	O
–	O
3	O
years	O
only	O
.	O

Hyperlipidemia	B-DS
was	O
associated	O
with	O
increased	O
risk	O
of	O
falls	O
over	O
the	O
whole	O
follow	O
-	O
up	O
period	O
of	O
0	O
–	O
10	O
years	O
—	O
HR	O
1	O
.	O
35	O
and	O
95	O
%	O
CI	O
(	O
1	O
.	O
01	O
–	O
1	O
.	O
80	O
),	O
P	O
=	O
0	O
.	O
042	O
—	O
and	O
borderline	O
increased	O
risk	O
at	O
1	O
–	O
3	O
years	O
[	O
HR	O
1	O
.	O
59	O
,	O
95	O
%	O
CI	O
(	O
1	O
.	O
00	O
–	O
2	O
.	O
55	O
),	O
P	O
=	O
0	O
.	O
052	O
].	O

Conversely	O
,	O
a	O
history	O
of	O
hypertension	B-DS
and	O
cancer	B-DS
showed	O
reduced	O
fall	O
risk	O
at	O
1	O
–	O
3	O
years	O
and	O
over	O
the	O
whole	O
follow	O
-	O
up	O
,	O
respectively	O
.	O

Univariate	O
analysis	O
of	O
risk	O
factors	O
for	O
poststroke	O
falls	O
over	O
time	O
after	O
discharge	O
.	O

0	O
–	O
365	O
days	O

366	O
–	O
1	O
,	O
095	O
days	O

1	O
,	O
096	O
–	O
1	O
,	O
825	O
days	O

0	O
–	O
3	O
,	O
650	O
days	O

OR	O
(	O
95	O
%	O
CI	O
)	O

HR	O
(	O
95	O
%	O
CI	O
)	O

HR	O
(	O
95	O
%	O
CI	O
)	O

HR	O
(	O
95	O
%	O
CI	O
)	O

Age	O

1	O
.	O
07	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
08	O
)***	O

1	O
.	O
06	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
07	O
)***	O

1	O
.	O
05	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
06	O
)***	O

1	O
.	O
04	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
05	O
)***	O

Sex	O

Male	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

Female	O

1	O
.	O
80	O
(	O
1	O
.	O
44	O
–	O
2	O
.	O
27	O
)***	O

1	O
.	O
82	O
(	O
1	O
.	O
47	O
–	O
2	O
.	O
24	O
)***	O

1	O
.	O
48	O
(	O
1	O
.	O
13	O
–	O
1	O
.	O
94	O
)**	O

1	O
.	O
58	O
(	O
1	O
.	O
40	O
–	O
1	O
.	O
77	O
)***	O


Type	O
of	O
stroke	B-DS

Infarct	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

Hemorrhage	O

1	O
.	O
02	O
(	O
0	O
.	O
71	O
–	O
1	O
.	O
46	O
)	O

0	O
.	O
76	O
(	O
0	O
.	O
53	O
–	O
1	O
.	O
11	O
)	O

0	O
.	O
81	O
(	O
0	O
.	O
51	O
–	O
1	O
.	O
30	O
)	O

0	O
.	O
93	O
(	O
0	O
.	O
77	O
–	O
1	O
.	O
13	O
)	O


Oxfordshire	O
community	O
stroke	B-DS
project	O
classification	O

Lacunar	B-DS
stroke	I-DS

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

Partial	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
32	O
(	O
1	O
.	O
00	O
–	O
1	O
.	O
74	O
)	O

1	O
.	O
04	O
(	O
0	O
.	O
82	O
–	O
1	O
.	O
32	O
)	O

0	O
.	O
84	O
(	O
0	O
.	O
61	O
–	O
1	O
.	O
15	O
)	O

0	O
.	O
99	O
(	O
0	O
.	O
86	O
–	O
1	O
.	O
13	O
)	O

Posterior	B-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
17	O
(	O
0	O
.	O
83	O
–	O
1	O
.	O
64	O
)	O

0	O
.	O
63	O
(	O
0	O
.	O
45	O
–	O
0	O
.	O
88	O
)**	O

0	O
.	O
80	O
(	O
0	O
.	O
55	O
–	O
1	O
.	O
17	O
)	O

0	O
.	O
79	O
(	O
0	O
.	O
66	O
–	O
0	O
.	O
95	O
)*	O

Total	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
06	O
(	O
0	O
.	O
72	O
–	O
1	O
.	O
56	O
)	O

0	O
.	O
77	O
(	O
0	O
.	O
53	O
–	O
1	O
.	O
11	O
)	O

0	O
.	O
51	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
88	O
)*	O

0	O
.	O
61	O
(	O
0	O
.	O
49	O
–	O
0	O
.	O
76	O
)***	O

Undetermined	O

0	O
.	O
99	O
(	O
0	O
.	O
51	O
–	O
1	O
.	O
93	O
)	O

1	O
.	O
16	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
95	O
)	O

0	O
.	O
75	O
(	O
0	O
.	O
33	O
–	O
1	O
.	O
72	O
)	O

0	O
.	O
84	O
(	O
0	O
.	O
60	O
–	O
1	O
.	O
18	O
)	O


Prestroke	O
modified	O
Rankin	O
score	O

0	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
–	O
2	O

1	O
.	O
88	O
(	O
1	O
.	O
45	O
–	O
2	O
.	O
44	O
)***	O

1	O
.	O
82	O
(	O
1	O
.	O
42	O
–	O
2	O
.	O
32	O
)***	O

1	O
.	O
75	O
(	O
1	O
.	O
28	O
–	O
2	O
.	O
40	O
)***	O

1	O
.	O
36	O
(	O
1	O
.	O
18	O
–	O
1	O
.	O
56	O
)***	O

3	O
–	O
5	O

2	O
.	O
13	O
(	O
1	O
.	O
60	O
–	O
2	O
.	O
84	O
)***	O

2	O
.	O
47	O
(	O
1	O
.	O
89	O
–	O
3	O
.	O
24	O
)***	O

1	O
.	O
11	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
85	O
)	O

1	O
.	O
27	O
(	O
1	O
.	O
07	O
–	O
1	O
.	O
51	O
)**	O


Previous	O
fall	O

2	O
.	O
54	O
(	O
1	O
.	O
96	O
–	O
3	O
.	O
30	O
)***	O

2	O
.	O
72	O
(	O
2	O
.	O
13	O
–	O
3	O
.	O
47	O
)***	O

1	O
.	O
65	O
(	O
1	O
.	O
11	O
–	O
2	O
.	O
48	O
)*	O

1	O
.	O
80	O
(	O
1	O
.	O
55	O
–	O
2	O
.	O
09	O
)***	O

Previous	O
fracture	O

2	O
.	O
24	O
(	O
1	O
.	O
66	O
–	O
3	O
.	O
03	O
)***	O

2	O
.	O
25	O
(	O
1	O
.	O
68	O
–	O
3	O
.	O
00	O
)***	O

1	O
.	O
94	O
(	O
1	O
.	O
27	O
–	O
2	O
.	O
97	O
)**	O

1	O
.	O
67	O
(	O
1	O
.	O
40	O
–	O
1	O
.	O
99	O
)***	O

Previous	O
stroke	B-DS
or	O
transient	B-DS
ischemic	I-DS
attack	I-DS

1	O
.	O
58	O
(	O
1	O
.	O
16	O
–	O
2	O
.	O
14	O
)**	O

1	O
.	O
23	O
(	O
0	O
.	O
90	O
–	O
1	O
.	O
69	O
)	O

1	O
.	O
35	O
(	O
0	O
.	O
89	O
–	O
2	O
.	O
05	O
)	O

1	O
.	O
18	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
41	O
)	O

Congestive	B-DS
heart	I-DS
failure	I-DS

1	O
.	O
46	O
(	O
1	O
.	O
00	O
–	O
2	O
.	O
14	O
)	O

1	O
.	O
61	O
(	O
1	O
.	O
09	O
–	O
2	O
.	O
36	O
)*	O

1	O
.	O
39	O
(	O
0	O
.	O
78	O
–	O
2	O
.	O
50	O
)	O

1	O
.	O
00	O
(	O
0	O
.	O
79	O
–	O
1	O
.	O
26	O
)	O

Coronary	B-DS
heart	I-DS
disease	I-DS
or	O
myocardial	B-DS
infarction	I-DS

1	O
.	O
43	O
(	O
1	O
.	O
09	O
–	O
1	O
.	O
88	O
)**	O

1	O
.	O
28	O
(	O
0	O
.	O
98	O
–	O
1	O
.	O
67	O
)	O

1	O
.	O
39	O
(	O
0	O
.	O
98	O
–	O
1	O
.	O
97	O
)	O

1	O
.	O
11	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
30	O
)	O

Atrial	B-DS
fibrillation	I-DS

1	O
.	O
63	O
(	O
1	O
.	O
23	O
–	O
2	O
.	O
17	O
)**	O

1	O
.	O
83	O
(	O
1	O
.	O
40	O
–	O
2	O
.	O
39	O
)***	O

1	O
.	O
17	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
80	O
)	O

1	O
.	O
27	O
(	O
1	O
.	O
08	O
–	O
1	O
.	O
49	O
)**	O

Diabetes	B-DS

1	O
.	O
47	O
(	O
1	O
.	O
06	O
–	O
2	O
.	O
04	O
)*	O

1	O
.	O
19	O
(	O
0	O
.	O
85	O
–	O
1	O
.	O
67	O
)	O

1	O
.	O
15	O
(	O
0	O
.	O
72	O
–	O
1	O
.	O
82	O
)	O

1	O
.	O
06	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
29	O
)	O

Hypertension	B-DS

1	O
.	O
53	O
(	O
1	O
.	O
22	O
–	O
1	O
.	O
92	O
)***	O

1	O
.	O
19	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
48	O
)	O

1	O
.	O
33	O
(	O
1	O
.	O
00	O
–	O
1	O
.	O
77	O
)	O

1	O
.	O
12	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
27	O
)	O

Peripheral	B-DS
vascular	I-DS
disease	I-DS

1	O
.	O
10	O
(	O
0	O
.	O
51	O
–	O
2	O
.	O
36	O
)	O

1	O
.	O
48	O
(	O
0	O
.	O
77	O
–	O
2	O
.	O
87	O
)	O

0	O
.	O
96	O
(	O
0	O
.	O
31	O
–	O
3	O
.	O
01	O
)	O

1	O
.	O
02	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
56	O
)	O

Chronic	B-DS
kidney	I-DS
disease	I-DS

2	O
.	O
57	O
(	O
1	O
.	O
61	O
–	O
4	O
.	O
10	O
)***	O

1	O
.	O
34	O
(	O
0	O
.	O
72	O
–	O
2	O
.	O
51	O
)	O

1	O
.	O
04	O
(	O
0	O
.	O
39	O
–	O
2	O
.	O
79	O
)	O

1	O
.	O
25	O
(	O
0	O
.	O
89	O
–	O
1	O
.	O
74	O
)	O

Chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS

1	O
.	O
71	O
(	O
1	O
.	O
08	O
–	O
2	O
.	O
71	O
)*	O

1	O
.	O
06	O
(	O
0	O
.	O
61	O
–	O
1	O
.	O
84	O
)	O

1	O
.	O
25	O
(	O
0	O
.	O
62	O
–	O
2	O
.	O
53	O
)	O

0	O
.	O
97	O
(	O
0	O
.	O
72	O
–	O
1	O
.	O
33	O
)	O

Dementia	B-DS

2	O
.	O
47	O
(	O
1	O
.	O
52	O
–	O
4	O
.	O
03	O
)***	O

2	O
.	O
07	O
(	O
1	O
.	O
19	O
–	O
3	O
.	O
60	O
)*	O

0	O
.	O
59	O
(	O
0	O
.	O
15	O
–	O
2	O
.	O
37	O
)	O

1	O
.	O
27	O
(	O
0	O
.	O
90	O
–	O
1	O
.	O
79	O
)	O

Hyperlipidemia	B-DS

1	O
.	O
45	O
(	O
0	O
.	O
90	O
–	O
2	O
.	O
33	O
)	O

1	O
.	O
45	O
(	O
0	O
.	O
93	O
–	O
2	O
.	O
25	O
)	O

1	O
.	O
46	O
(	O
0	O
.	O
82	O
–	O
2	O
.	O
62	O
)	O

1	O
.	O
24	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
63	O
)	O

Cancer	B-DS

1	O
.	O
00	O
(	O
0	O
.	O
70	O
–	O
1	O
.	O
43	O
)	O

0	O
.	O
96	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
38	O
)	O

1	O
.	O
01	O
(	O
0	O
.	O
62	O
–	O
1	O
.	O
63	O
)	O

0	O
.	O
85	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
04	O
)	O

*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

Multivariable	O
analysis	O
of	O
risk	O
factors	O
for	O
poststroke	O
falls	O
over	O
time	O
after	O
discharge	O
.	O

0	O
–	O
365	O
days	O

366	O
–	O
1	O
,	O
095	O
days	O

1	O
,	O
096	O
–	O
1	O
,	O
825	O
days	O

0	O
–	O
3	O
,	O
650	O
days	O

OR	O
(	O
95	O
%	O
CI	O
)	O

P	O

HR	O
(	O
95	O
%	O
CI	O
)	O

P	O

HR	O
(	O
95	O
%	O
CI	O
)	O

P	O

HR	O
(	O
95	O
%	O
CI	O
)	O

P	O

Age	O

1	O
.	O
06	O
(	O
1	O
.	O
04	O
–	O
1	O
.	O
07	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
05	O
(	O
1	O
.	O
04	O
–	O
1	O
.	O
06	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
05	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
06	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
04	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
04	O
)	O

<	O
0	O
.	O
001	O

Sex	O

Male	O

1	O
.	O
00	O

0	O
.	O
031	O

1	O
.	O
00	O

0	O
.	O
024	O

1	O
.	O
00	O

0	O
.	O
275	O

1	O
.	O
00	O

<	O
0	O
.	O
001	O

Female	O

1	O
.	O
31	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
67	O
)	O

1	O
.	O
29	O
(	O
1	O
.	O
04	O
–	O
1	O
.	O
62	O
)	O

1	O
.	O
17	O
(	O
0	O
.	O
88	O
–	O
1	O
.	O
56	O
)	O

1	O
.	O
29	O
(	O
1	O
.	O
14	O
–	O
1	O
.	O
47	O
)	O


Type	O
of	O
stroke	B-DS

Infarct	O

1	O
.	O
00	O

0	O
.	O
254	O

1	O
.	O
00	O

0	O
.	O
673	O

1	O
.	O
00	O

0	O
.	O
762	O

1	O
.	O
00	O

0	O
.	O
469	O

Hemorrhage	O

1	O
.	O
24	O
(	O
0	O
.	O
86	O
–	O
1	O
.	O
81	O
)	O

0	O
.	O
92	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
35	O
)	O

0	O
.	O
93	O
(	O
0	O
.	O
57	O
–	O
1	O
.	O
51	O
)	O

1	O
.	O
08	O
(	O
0	O
.	O
88	O
–	O
1	O
.	O
32	O
)	O


Oxfordshire	O
community	O
stroke	B-DS
project	O
classification	O

Lacunar	B-DS
stroke	I-DS

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

Partial	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
25	O
(	O
0	O
.	O
94	O
–	O
1	O
.	O
66	O
)	O

0	O
.	O
127	O

0	O
.	O
99	O
(	O
0	O
.	O
78	O
–	O
1	O
.	O
26	O
)	O

0	O
.	O
962	O

0	O
.	O
80	O
(	O
0	O
.	O
58	O
–	O
1	O
.	O
10	O
)	O

0	O
.	O
168	O

0	O
.	O
94	O
(	O
0	O
.	O
82	O
–	O
1	O
.	O
08	O
)	O

0	O
.	O
393	O

Posterior	B-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
35	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
92	O
)	O

0	O
.	O
090	O

0	O
.	O
75	O
(	O
0	O
.	O
54	O
–	O
1	O
.	O
06	O
)	O

0	O
.	O
101	O

0	O
.	O
90	O
(	O
0	O
.	O
61	O
–	O
1	O
.	O
33	O
)	O

0	O
.	O
603	O

0	O
.	O
87	O
(	O
0	O
.	O
72	O
–	O
1	O
.	O
04	O
)	O

0	O
.	O
125	O

Total	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
02	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
51	O
)	O

0	O
.	O
935	O

0	O
.	O
74	O
(	O
0	O
.	O
51	O
–	O
1	O
.	O
08	O
)	O

0	O
.	O
122	O

0	O
.	O
48	O
(	O
0	O
.	O
27	O
–	O
0	O
.	O
84	O
)	O

0	O
.	O
009	O

0	O
.	O
58	O
(	O
0	O
.	O
46	O
–	O
0	O
.	O
72	O
)	O

<	O
0	O
.	O
001	O

Undetermined	O

1	O
.	O
05	O
(	O
0	O
.	O
53	O
–	O
2	O
.	O
10	O
)	O

0	O
.	O
886	O

1	O
.	O
29	O
(	O
0	O
.	O
76	O
–	O
2	O
.	O
20	O
)	O

0	O
.	O
348	O

0	O
.	O
91	O
(	O
0	O
.	O
39	O
–	O
2	O
.	O
11	O
)	O

0	O
.	O
817	O

0	O
.	O
90	O
(	O
0	O
.	O
64	O
–	O
1	O
.	O
28	O
)	O

0	O
.	O
560	O


Prestroke	O
modified	O
Rankin	O
score	O

0	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
–	O
2	O

1	O
.	O
25	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
65	O
)	O

0	O
.	O
112	O

1	O
.	O
27	O
(	O
0	O
.	O
98	O
–	O
1	O
.	O
64	O
)	O

0	O
.	O
070	O

1	O
.	O
32	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
83	O
)	O

0	O
.	O
103	O

1	O
.	O
06	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
22	O
)	O

0	O
.	O
471	O

3	O
–	O
5	O

1	O
.	O
05	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
46	O
)	O

0	O
.	O
767	O

1	O
.	O
31	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
78	O
)	O

0	O
.	O
087	O

0	O
.	O
74	O
(	O
0	O
.	O
43	O
–	O
1	O
.	O
29	O
)	O

0	O
.	O
287	O

0	O
.	O
80	O
(	O
0	O
.	O
67	O
–	O
0	O
.	O
97	O
)	O

0	O
.	O
023	O

Previous	O
fall	O

1	O
.	O
49	O
(	O
1	O
.	O
03	O
–	O
2	O
.	O
17	O
)	O

0	O
.	O
035	O

1	O
.	O
65	O
(	O
1	O
.	O
17	O
–	O
2	O
.	O
33	O
)	O

0	O
.	O
004	O

0	O
.	O
94	O
(	O
0	O
.	O
52	O
–	O
1	O
.	O
69	O
)	O

0	O
.	O
837	O

1	O
.	O
38	O
(	O
1	O
.	O
11	O
–	O
1	O
.	O
71	O
)	O

0	O
.	O
003	O

Previous	O
fracture	O

1	O
.	O
03	O
(	O
0	O
.	O
68	O
–	O
1	O
.	O
57	O
)	O

0	O
.	O
882	O

1	O
.	O
04	O
(	O
0	O
.	O
71	O
–	O
1	O
.	O
54	O
)	O

0	O
.	O
830	O

1	O
.	O
60	O
(	O
0	O
.	O
88	O
–	O
2	O
.	O
92	O
)	O

0	O
.	O
127	O

1	O
.	O
05	O
(	O
0	O
.	O
82	O
–	O
1	O
.	O
33	O
)	O

0	O
.	O
702	O

Previous	O
stroke	B-DS
or	O
transient	B-DS
ischemic	I-DS
attack	I-DS

1	O
.	O
26	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
75	O
)	O

0	O
.	O
159	O

0	O
.	O
96	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
34	O
)	O

0	O
.	O
817	O

1	O
.	O
15	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
79	O
)	O

0	O
.	O
521	O

1	O
.	O
08	O
(	O
0	O
.	O
90	O
–	O
1	O
.	O
30	O
)	O

0	O
.	O
413	O

Congestive	B-DS
heart	I-DS
failure	I-DS

0	O
.	O
81	O
(	O
0	O
.	O
52	O
–	O
1	O
.	O
25	O
)	O

0	O
.	O
334	O

1	O
.	O
07	O
(	O
0	O
.	O
70	O
–	O
1	O
.	O
65	O
)	O

0	O
.	O
745	O

1	O
.	O
11	O
(	O
0	O
.	O
60	O
–	O
2	O
.	O
10	O
)	O

0	O
.	O
744	O

0	O
.	O
77	O
(	O
0	O
.	O
60	O
–	O
1	O
.	O
00	O
)	O

0	O
.	O
054	O

Coronary	B-DS
heart	I-DS
disease	I-DS
or	O
myocardial	B-DS
infarction	I-DS

1	O
.	O
04	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
42	O
)	O

0	O
.	O
816	O

0	O
.	O
99	O
(	O
0	O
.	O
73	O
–	O
1	O
.	O
35	O
)	O

0	O
.	O
950	O

1	O
.	O
18	O
(	O
0	O
.	O
79	O
–	O
1	O
.	O
77	O
)	O

0	O
.	O
417	O

1	O
.	O
02	O
(	O
0	O
.	O
85	O
–	O
1	O
.	O
22	O
)	O

0	O
.	O
839	O

Atrial	B-DS
fibrillation	I-DS

1	O
.	O
07	O
(	O
0	O
.	O
77	O
–	O
1	O
.	O
49	O
)	O

0	O
.	O
677	O

1	O
.	O
46	O
(	O
1	O
.	O
08	O
–	O
1	O
.	O
98	O
)	O

0	O
.	O
015	O

0	O
.	O
87	O
(	O
0	O
.	O
54	O
–	O
1	O
.	O
40	O
)	O

0	O
.	O
566	O

1	O
.	O
14	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
37	O
)	O

0	O
.	O
154	O

Diabetes	B-DS

1	O
.	O
25	O
(	O
0	O
.	O
88	O
–	O
1	O
.	O
79	O
)	O

0	O
.	O
220	O

1	O
.	O
15	O
(	O
0	O
.	O
80	O
–	O
1	O
.	O
65	O
)	O

0	O
.	O
449	O

1	O
.	O
04	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
69	O
)	O

0	O
.	O
892	O

1	O
.	O
06	O
(	O
0	O
.	O
86	O
–	O
1	O
.	O
30	O
)	O

0	O
.	O
614	O

Hypertension	B-DS

0	O
.	O
96	O
(	O
0	O
.	O
73	O
–	O
1	O
.	O
26	O
)	O

0	O
.	O
773	O

0	O
.	O
73	O
(	O
0	O
.	O
56	O
–	O
0	O
.	O
94	O
)	O

0	O
.	O
016	O

0	O
.	O
98	O
(	O
0	O
.	O
70	O
–	O
1	O
.	O
38	O
)	O

0	O
.	O
910	O

0	O
.	O
88	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
02	O
)	O

0	O
.	O
100	O

Peripheral	B-DS
vascular	I-DS
disease	I-DS

0	O
.	O
74	O
(	O
0	O
.	O
33	O
–	O
1	O
.	O
64	O
)	O

0	O
.	O
454	O

1	O
.	O
27	O
(	O
0	O
.	O
64	O
–	O
2	O
.	O
50	O
)	O

0	O
.	O
492	O

0	O
.	O
86	O
(	O
0	O
.	O
27	O
–	O
2	O
.	O
75	O
)	O

0	O
.	O
804	O

0	O
.	O
96	O
(	O
0	O
.	O
62	O
–	O
1	O
.	O
48	O
)	O

0	O
.	O
849	O

Chronic	B-DS
kidney	I-DS
disease	I-DS

1	O
.	O
98	O
(	O
1	O
.	O
19	O
–	O
3	O
.	O
30	O
)	O

0	O
.	O
009	O

0	O
.	O
97	O
(	O
0	O
.	O
50	O
–	O
1	O
.	O
87	O
)	O

0	O
.	O
917	O

0	O
.	O
82	O
(	O
0	O
.	O
29	O
–	O
2	O
.	O
28	O
)	O

0	O
.	O
698	O

1	O
.	O
23	O
(	O
0	O
.	O
86	O
–	O
1	O
.	O
74	O
)	O

0	O
.	O
255	O

Chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS

1	O
.	O
40	O
(	O
0	O
.	O
86	O
–	O
2	O
.	O
27	O
)	O

0	O
.	O
171	O

0	O
.	O
84	O
(	O
0	O
.	O
47	O
–	O
1	O
.	O
47	O
)	O

0	O
.	O
536	O

1	O
.	O
04	O
(	O
0	O
.	O
50	O
–	O
2	O
.	O
15	O
)	O

0	O
.	O
917	O

0	O
.	O
92	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
26	O
)	O

0	O
.	O
613	O

Dementia	B-DS

1	O
.	O
15	O
(	O
0	O
.	O
68	O
–	O
1	O
.	O
96	O
)	O

0	O
.	O
601	O

0	O
.	O
80	O
(	O
0	O
.	O
45	O
–	O
1	O
.	O
43	O
)	O

0	O
.	O
449	O

0	O
.	O
37	O
(	O
0	O
.	O
09	O
–	O
1	O
.	O
52	O
)	O

0	O
.	O
167	O

0	O
.	O
86	O
(	O
0	O
.	O
60	O
–	O
1	O
.	O
23	O
)	O

0	O
.	O
406	O

Hyperlipidemia	B-DS

1	O
.	O
37	O
(	O
0	O
.	O
81	O
–	O
2	O
.	O
30	O
)	O

0	O
.	O
238	O

1	O
.	O
59	O
(	O
1	O
.	O
00	O
–	O
2	O
.	O
55	O
)	O

0	O
.	O
052	O

1	O
.	O
39	O
(	O
0	O
.	O
74	O
–	O
2	O
.	O
60	O
)	O

0	O
.	O
309	O

1	O
.	O
35	O
(	O
1	O
.	O
01	O
–	O
1	O
.	O
80	O
)	O

0	O
.	O
042	O

Cancer	B-DS

0	O
.	O
79	O
(	O
0	O
.	O
55	O
–	O
1	O
.	O
15	O
)	O

0	O
.	O
216	O

0	O
.	O
82	O
(	O
0	O
.	O
57	O
–	O
1	O
.	O
19	O
)	O

0	O
.	O
296	O

0	O
.	O
80	O
(	O
0	O
.	O
49	O
–	O
1	O
.	O
31	O
)	O

0	O
.	O
373	O

0	O
.	O
76	O
(	O
0	O
.	O
61	O
–	O
0	O
.	O
93	O
)	O

0	O
.	O
008	O

Table	O
4	O
displays	O
the	O
results	O
of	O
the	O
univariate	O
analysis	O
for	O
risk	O
factors	O
for	O
poststroke	O
fractures	O
after	O
discharge	O
over	O
the	O
prespecified	O
time	O
periods	O
.	O

Once	O
again	O
,	O
many	O
factors	O
were	O
associated	O
with	O
post	O
-	O
discharge	O
fracture	O
risk	O
in	O
these	O
unadjusted	O
analyses	O
,	O
with	O
the	O
risk	O
profile	O
changing	O
over	O
follow	O
-	O
up	O
.	O

Table	O
5	O
shows	O
the	O
results	O
of	O
the	O
fully	O
adjusted	O
multivariable	O
analyses	O
for	O
poststroke	O
fracture	O
risk	O
factors	O
after	O
discharge	O
.	O

Increasing	O
age	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
fractures	O
at	O
all	O
four	O
time	O
periods	O
.	O

Female	O
sex	O
and	O
a	O
history	O
of	O
falls	O
were	O
also	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
fractures	O
at	O
0	O
–	O
1	O
,	O
1	O
–	O
3	O
,	O
and	O
0	O
–	O
10	O
years	O
.	O

Atrial	B-DS
fibrillation	I-DS
was	O
also	O
associated	O
with	O
increased	O
risk	O
of	O
fracture	O
from	O
1	O
to	O
3	O
years	O
after	O
discharge	O
only	O
[	O
HR	O
1	O
.	O
62	O
,	O
95	O
%	O
CI	O
(	O
1	O
.	O
09	O
–	O
2	O
.	O
40	O
),	O
P	O
=	O
0	O
.	O
017	O
]	O
and	O
previous	O
stroke	B-DS
/	O
TIA	B-DS
were	O
associated	O
with	O
increased	O
risk	O
over	O
the	O
whole	O
follow	O
-	O
up	O
[	O
HR	O
1	O
.	O
27	O
,	O
95	O
%	O
CI	O
(	O
1	O
.	O
01	O
–	O
1	O
.	O
60	O
),	O
P	O
=	O
0	O
.	O
041	O
]	O
(	O
also	O
just	O
failing	O
to	O
reach	O
statistical	O
significance	O
at	O
0	O
–	O
1	O
years	O
after	O
discharge	O
).	O

Once	O
again	O
,	O
TACS	B-DS
were	O
associated	O
with	O
decreased	O
risk	O
of	O
fracture	O
from	O
1	O
to	O
3	O
years	O
and	O
over	O
the	O
whole	O
follow	O
-	O
up	O
period	O
(	O
again	O
with	O
borderline	O
significance	O
during	O
the	O
3	O
–	O
5	O
-	O
year	O
time	O
period	O
).	O

A	O
prestroke	O
mRS	O
score	O
of	O
3	O
–	O
5	O
was	O
also	O
associated	O
with	O
reduced	O
risk	O
of	O
fracture	O
over	O
the	O
whole	O
follow	O
-	O
up	O
of	O
0	O
–	O
10	O
years	O
.	O

Univariate	O
analysis	O
of	O
risk	O
factors	O
for	O
poststroke	O
fractures	O
over	O
time	O
after	O
discharge	O
.	O

0	O
–	O
365	O
days	O

366	O
–	O
1	O
,	O
095	O
days	O

1	O
,	O
096	O
–	O
1	O
,	O
825	O
days	O

0	O
–	O
3	O
,	O
650	O
days	O

OR	O
(	O
95	O
%	O
CI	O
)	O

HR	O
(	O
95	O
%	O
CI	O
)	O

HR	O
(	O
95	O
%	O
CI	O
)	O

HR	O
(	O
95	O
%	O
CI	O
)	O

Age	O

1	O
.	O
07	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
09	O
)***	O

1	O
.	O
04	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
06	O
)***	O

1	O
.	O
05	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
06	O
)***	O

1	O
.	O
03	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
04	O
)***	O

Sex	O

Male	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

Female	O

2	O
.	O
30	O
(	O
1	O
.	O
73	O
–	O
3	O
.	O
05	O
)***	O

1	O
.	O
89	O
(	O
1	O
.	O
42	O
–	O
2	O
.	O
51	O
)***	O

1	O
.	O
75	O
(	O
1	O
.	O
20	O
–	O
2	O
.	O
55	O
)**	O

1	O
.	O
88	O
(	O
1	O
.	O
60	O
–	O
2	O
.	O
20	O
)***	O


Type	O
of	O
stroke	B-DS

Infarct	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

Hemorrhage	O

1	O
.	O
05	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
60	O
)	O

0	O
.	O
75	O
(	O
0	O
.	O
45	O
–	O
1	O
.	O
25	O
)	O

0	O
.	O
71	O
(	O
0	O
.	O
36	O
–	O
1	O
.	O
40	O
)	O

0	O
.	O
93	O
(	O
0	O
.	O
72	O
–	O
1	O
.	O
20	O
)	O


Oxfordshire	O
community	O
stroke	B-DS
project	O
classification	O

Lacunar	B-DS
stroke	I-DS

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

Partial	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
21	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
69	O
)	O

0	O
.	O
86	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
18	O
)	O

0	O
.	O
95	O
(	O
0	O
.	O
62	O
–	O
1	O
.	O
48	O
)	O

0	O
.	O
97	O
(	O
0	O
.	O
81	O
–	O
1	O
.	O
16	O
)	O

Posterior	B-DS
circulation	I-DS
stroke	I-DS

0	O
.	O
99	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
50	O
)	O

0	O
.	O
62	O
(	O
0	O
.	O
40	O
–	O
0	O
.	O
95	O
)*	O

0	O
.	O
93	O
(	O
0	O
.	O
55	O
–	O
1	O
.	O
56	O
)	O

0	O
.	O
83	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
04	O
)	O

Total	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
09	O
(	O
0	O
.	O
70	O
–	O
1	O
.	O
70	O
)	O

0	O
.	O
56	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
97	O
)*	O

0	O
.	O
49	O
(	O
0	O
.	O
22	O
–	O
1	O
.	O
09	O
)	O

0	O
.	O
62	O
(	O
0	O
.	O
46	O
–	O
0	O
.	O
82	O
)*	O

Undetermined	O

1	O
.	O
37	O
(	O
0	O
.	O
69	O
–	O
2	O
.	O
71	O
)	O

1	O
.	O
22	O
(	O
0	O
.	O
63	O
–	O
2	O
.	O
36	O
)	O

1	O
.	O
32	O
(	O
0	O
.	O
52	O
–	O
3	O
.	O
35	O
)	O

1	O
.	O
04	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
56	O
)	O


Prestroke	O
modified	O
Rankin	O
score	O

0	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
–	O
2	O

2	O
.	O
13	O
(	O
1	O
.	O
57	O
–	O
2	O
.	O
89	O
)***	O

1	O
.	O
56	O
(	O
1	O
.	O
12	O
–	O
2	O
.	O
18	O
)**	O

1	O
.	O
45	O
(	O
0	O
.	O
93	O
–	O
2	O
.	O
27	O
)	O

1	O
.	O
29	O
(	O
1	O
.	O
07	O
–	O
1	O
.	O
56	O
)**	O

3	O
–	O
5	O

2	O
.	O
34	O
(	O
1	O
.	O
67	O
–	O
3	O
.	O
28	O
)***	O

1	O
.	O
66	O
(	O
1	O
.	O
11	O
–	O
2	O
.	O
48	O
)*	O

1	O
.	O
31	O
(	O
0	O
.	O
70	O
–	O
2	O
.	O
45	O
)	O

1	O
.	O
19	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
49	O
)	O

Previous	O
fall	O

4	O
.	O
15	O
(	O
3	O
.	O
13	O
–	O
5	O
.	O
49	O
)***	O

3	O
.	O
01	O
(	O
2	O
.	O
18	O
–	O
4	O
.	O
15	O
)***	O

1	O
.	O
67	O
(	O
0	O
.	O
97	O
–	O
2	O
.	O
87	O
)	O

2	O
.	O
32	O
(	O
1	O
.	O
93	O
–	O
2	O
.	O
78	O
)***	O

Previous	O
fracture	O

3	O
.	O
76	O
(	O
2	O
.	O
76	O
–	O
5	O
.	O
13	O
)***	O

2	O
.	O
33	O
(	O
1	O
.	O
58	O
–	O
3	O
.	O
43	O
)***	O

2	O
.	O
10	O
(	O
1	O
.	O
20	O
–	O
3	O
.	O
67	O
)**	O

2	O
.	O
15	O
(	O
1	O
.	O
74	O
–	O
2	O
.	O
65	O
)***	O

Previous	O
stroke	B-DS
or	O
transient	B-DS
ischemic	I-DS
attack	I-DS

1	O
.	O
88	O
(	O
1	O
.	O
34	O
–	O
2	O
.	O
65	O
)***	O

1	O
.	O
37	O
(	O
0	O
.	O
91	O
–	O
2	O
.	O
07	O
)	O

1	O
.	O
66	O
(	O
0	O
.	O
98	O
–	O
2	O
.	O
82	O
)	O

1	O
.	O
43	O
(	O
1	O
.	O
15	O
–	O
1	O
.	O
78	O
)**	O

Congestive	B-DS
heart	I-DS
failure	I-DS

1	O
.	O
80	O
(	O
1	O
.	O
19	O
–	O
2	O
.	O
74	O
)**	O

1	O
.	O
69	O
(	O
1	O
.	O
01	O
–	O
2	O
.	O
81	O
)*	O

1	O
.	O
96	O
(	O
0	O
.	O
99	O
–	O
3	O
.	O
86	O
)	O

1	O
.	O
25	O
(	O
0	O
.	O
94	O
–	O
1	O
.	O
65	O
)	O

Coronary	B-DS
heart	I-DS
disease	I-DS
or	O
myocardial	B-DS
infarction	I-DS

1	O
.	O
40	O
(	O
1	O
.	O
01	O
–	O
1	O
.	O
93	O
)*	O

1	O
.	O
43	O
(	O
1	O
.	O
01	O
–	O
2	O
.	O
02	O
)*	O

1	O
.	O
67	O
(	O
1	O
.	O
07	O
–	O
2	O
.	O
62	O
)*	O

1	O
.	O
19	O
(	O
0	O
.	O
98	O
–	O
1	O
.	O
45	O
)	O

Atrial	B-DS
fibrillation	I-DS

1	O
.	O
76	O
(	O
1	O
.	O
26	O
–	O
2	O
.	O
44	O
)**	O

2	O
.	O
04	O
(	O
1	O
.	O
44	O
–	O
2	O
.	O
89	O
)***	O

1	O
.	O
10	O
(	O
0	O
.	O
61	O
–	O
2	O
.	O
00	O
)	O

1	O
.	O
39	O
(	O
1	O
.	O
13	O
–	O
1	O
.	O
71	O
)**	O

Diabetes	B-DS

1	O
.	O
29	O
(	O
0	O
.	O
86	O
–	O
1	O
.	O
94	O
)	O

1	O
.	O
50	O
(	O
0	O
.	O
99	O
–	O
2	O
.	O
28	O
)	O

0	O
.	O
61	O
(	O
0	O
.	O
27	O
–	O
1	O
.	O
38	O
)	O

1	O
.	O
09	O
(	O
0	O
.	O
84	O
–	O
1	O
.	O
40	O
)	O

Hypertension	B-DS

1	O
.	O
51	O
(	O
1	O
.	O
15	O
–	O
1	O
.	O
97	O
)**	O

1	O
.	O
44	O
(	O
1	O
.	O
08	O
–	O
1	O
.	O
92	O
)*	O

1	O
.	O
46	O
(	O
0	O
.	O
99	O
–	O
2	O
.	O
14	O
)	O

1	O
.	O
23	O
(	O
1	O
.	O
04	O
–	O
1	O
.	O
44	O
)*	O

Peripheral	B-DS
vascular	I-DS
disease	I-DS

2	O
.	O
12	O
(	O
1	O
.	O
07	O
–	O
4	O
.	O
23	O
)*	O

1	O
.	O
55	O
(	O
0	O
.	O
64	O
–	O
3	O
.	O
76	O
)	O

0	O
.	O
59	O
(	O
0	O
.	O
08	O
–	O
4	O
.	O
25	O
)	O

1	O
.	O
30	O
(	O
0	O
.	O
79	O
–	O
2	O
.	O
14	O
)	O

Chronic	B-DS
kidney	I-DS
disease	I-DS

2	O
.	O
40	O
(	O
1	O
.	O
37	O
–	O
4	O
.	O
19	O
)**	O

1	O
.	O
18	O
(	O
0	O
.	O
49	O
–	O
2	O
.	O
87	O
)	O

0	O
.	O
45	O
(	O
0	O
.	O
06	O
–	O
3	O
.	O
24	O
)	O

1	O
.	O
21	O
(	O
0	O
.	O
78	O
–	O
1	O
.	O
87	O
)	O

Chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS

1	O
.	O
74	O
(	O
1	O
.	O
02	O
–	O
2	O
.	O
98	O
)*	O

0	O
.	O
74	O
(	O
0	O
.	O
31	O
–	O
1	O
.	O
80	O
)	O

1	O
.	O
14	O
(	O
0	O
.	O
42	O
–	O
3	O
.	O
08	O
)	O

0	O
.	O
98	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
46	O
)	O

Dementia	B-DS

1	O
.	O
97	O
(	O
1	O
.	O
05	O
–	O
3	O
.	O
67	O
)*	O

1	O
.	O
35	O
(	O
0	O
.	O
56	O
–	O
3	O
.	O
27	O
)	O

1	O
.	O
07	O
(	O
0	O
.	O
26	O
–	O
4	O
.	O
33	O
)	O

1	O
.	O
10	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
76	O
)	O

Hyperlipidemia	B-DS

1	O
.	O
29	O
(	O
0	O
.	O
71	O
–	O
2	O
.	O
33	O
)	O

1	O
.	O
48	O
(	O
0	O
.	O
83	O
–	O
2	O
.	O
65	O
)	O

1	O
.	O
08	O
(	O
0	O
.	O
44	O
–	O
2	O
.	O
66	O
)	O

1	O
.	O
13	O
(	O
0	O
.	O
78	O
–	O
1	O
.	O
63	O
)	O

Cancer	B-DS

0	O
.	O
89	O
(	O
0	O
.	O
57	O
–	O
1	O
.	O
39	O
)	O

1	O
.	O
24	O
(	O
0	O
.	O
80	O
–	O
1	O
.	O
93	O
)	O

1	O
.	O
29	O
(	O
0	O
.	O
71	O
–	O
2	O
.	O
35	O
)	O

0	O
.	O
94	O
(	O
0	O
.	O
73	O
–	O
1	O
.	O
21	O
)	O

*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

Multivariable	O
analysis	O
of	O
risk	O
factors	O
for	O
poststroke	O
fractures	O
over	O
time	O
after	O
discharge	O
.	O

0	O
–	O
365	O
days	O

366	O
–	O
1	O
,	O
095	O
days	O

1	O
,	O
096	O
–	O
1	O
,	O
825	O
days	O

0	O
–	O
3	O
,	O
650	O
days	O

OR	O
(	O
95	O
%	O
CI	O
)	O

P	O

HR	O
(	O
95	O
%	O
CI	O
)	O

P	O

HR	O
(	O
95	O
%	O
CI	O
)	O

P	O

HR	O
(	O
95	O
%	O
CI	O
)	O

P	O

Age	O

1	O
.	O
05	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
07	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
03	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
05	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
04	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
06	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
03	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
03	O
)	O

<	O
0	O
.	O
001	O

Sex	O

Male	O

1	O
.	O
00	O

0	O
.	O
003	O

1	O
.	O
00	O

0	O
.	O
007	O

1	O
.	O
00	O

0	O
.	O
098	O

1	O
.	O
00	O

<	O
0	O
.	O
001	O

Female	O

1	O
.	O
58	O
(	O
1	O
.	O
16	O
–	O
2	O
.	O
13	O
)	O

1	O
.	O
52	O
(	O
1	O
.	O
12	O
–	O
2	O
.	O
05	O
)	O

1	O
.	O
40	O
(	O
0	O
.	O
94	O
–	O
2	O
.	O
08	O
)	O

1	O
.	O
59	O
(	O
1	O
.	O
34	O
–	O
1	O
.	O
88	O
)	O


Type	O
of	O
stroke	B-DS

Infarct	O

1	O
.	O
00	O

0	O
.	O
251	O

1	O
.	O
00	O

0	O
.	O
630	O

1	O
.	O
00	O

0	O
.	O
425	O

1	O
.	O
00	O

0	O
.	O
768	O

Hemorrhage	O

1	O
.	O
30	O
(	O
0	O
.	O
83	O
–	O
2	O
.	O
02	O
)	O

0	O
.	O
88	O
(	O
0	O
.	O
52	O
–	O
1	O
.	O
49	O
)	O

0	O
.	O
75	O
(	O
0	O
.	O
37	O
–	O
1	O
.	O
52	O
)	O

1	O
.	O
04	O
(	O
0	O
.	O
80	O
–	O
1	O
.	O
36	O
)	O


Oxfordshire	O
community	O
stroke	B-DS
project	O
classification	O

Lacunar	B-DS
stroke	I-DS

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

Partial	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
14	O
(	O
0	O
.	O
82	O
–	O
1	O
.	O
60	O
)	O

0	O
.	O
439	O

0	O
.	O
82	O
(	O
0	O
.	O
60	O
–	O
1	O
.	O
13	O
)	O

0	O
.	O
230	O

0	O
.	O
91	O
(	O
0	O
.	O
59	O
–	O
1	O
.	O
41	O
)	O

0	O
.	O
668	O

0	O
.	O
93	O
(	O
0	O
.	O
77	O
–	O
1	O
.	O
11	O
)	O

0	O
.	O
422	O

Posterior	B-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
17	O
(	O
0	O
.	O
77	O
–	O
1	O
.	O
80	O
)	O

0	O
.	O
465	O

0	O
.	O
72	O
(	O
0	O
.	O
47	O
–	O
1	O
.	O
12	O
)	O

0	O
.	O
144	O

1	O
.	O
07	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
81	O
)	O

0	O
.	O
805	O

0	O
.	O
92	O
(	O
0	O
.	O
72	O
–	O
1	O
.	O
16	O
)	O

0	O
.	O
461	O

Total	B-DS
anterior	I-DS
circulation	I-DS
stroke	I-DS

1	O
.	O
05	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
65	O
)	O

0	O
.	O
848	O

0	O
.	O
54	O
(	O
0	O
.	O
32	O
–	O
0	O
.	O
94	O
)	O

0	O
.	O
028	O

0	O
.	O
45	O
(	O
0	O
.	O
20	O
–	O
1	O
.	O
02	O
)	O

0	O
.	O
056	O

0	O
.	O
58	O
(	O
0	O
.	O
43	O
–	O
0	O
.	O
78	O
)	O

<	O
0	O
.	O
001	O

Undetermined	O

1	O
.	O
45	O
(	O
0	O
.	O
71	O
–	O
2	O
.	O
96	O
)	O

0	O
.	O
308	O

1	O
.	O
39	O
(	O
0	O
.	O
70	O
–	O
2	O
.	O
75	O
)	O

0	O
.	O
342	O

1	O
.	O
69	O
(	O
0	O
.	O
65	O
–	O
4	O
.	O
40	O
)	O

0	O
.	O
285	O

1	O
.	O
11	O
(	O
0	O
.	O
73	O
–	O
1	O
.	O
69	O
)	O

0	O
.	O
628	O


Prestroke	O
modified	O
Rankin	O
score	O

0	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
.	O
00	O

1	O
–	O
2	O

1	O
.	O
31	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
82	O
)	O

0	O
.	O
102	O

1	O
.	O
08	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
53	O
)	O

0	O
.	O
676	O

1	O
.	O
07	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
71	O
)	O

0	O
.	O
787	O

0	O
.	O
96	O
(	O
0	O
.	O
79	O
–	O
1	O
.	O
17	O
)	O

0	O
.	O
705	O

3	O
–	O
5	O

1	O
.	O
01	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
49	O
)	O

0	O
.	O
963	O

0	O
.	O
87	O
(	O
0	O
.	O
55	O
–	O
1	O
.	O
35	O
)	O

0	O
.	O
525	O

0	O
.	O
82	O
(	O
0	O
.	O
42	O
–	O
1	O
.	O
63	O
)	O

0	O
.	O
577	O

0	O
.	O
71	O
(	O
0	O
.	O
55	O
–	O
0	O
.	O
90	O
)	O

0	O
.	O
006	O

Previous	O
fall	O

2	O
.	O
20	O
(	O
1	O
.	O
45	O
–	O
3	O
.	O
33	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
32	O
(	O
1	O
.	O
47	O
–	O
3	O
.	O
64	O
)	O

<	O
0	O
.	O
001	O

0	O
.	O
81	O
(	O
0	O
.	O
37	O
–	O
1	O
.	O
79	O
)	O

0	O
.	O
604	O

1	O
.	O
77	O
(	O
1	O
.	O
36	O
–	O
2	O
.	O
30	O
)	O

<	O
0	O
.	O
001	O

Previous	O
fracture	O

1	O
.	O
33	O
(	O
0	O
.	O
86	O
–	O
2	O
.	O
08	O
)	O

0	O
.	O
202	O

0	O
.	O
93	O
(	O
0	O
.	O
55	O
–	O
1	O
.	O
56	O
)	O

0	O
.	O
781	O

1	O
.	O
84	O
(	O
0	O
.	O
83	O
–	O
4	O
.	O
07	O
)	O

0	O
.	O
132	O

1	O
.	O
14	O
(	O
0	O
.	O
85	O
–	O
1	O
.	O
53	O
)	O

0	O
.	O
376	O

Previous	O
stroke	B-DS
or	O
transient	B-DS
ischemic	I-DS
attack	I-DS

1	O
.	O
44	O
(	O
0	O
.	O
99	O
–	O
2	O
.	O
09	O
)	O

0	O
.	O
054	O

1	O
.	O
02	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
56	O
)	O

0	O
.	O
945	O

1	O
.	O
43	O
(	O
0	O
.	O
82	O
–	O
2	O
.	O
50	O
)	O

0	O
.	O
206	O

1	O
.	O
27	O
(	O
1	O
.	O
01	O
–	O
1	O
.	O
60	O
)	O

0	O
.	O
041	O

Congestive	B-DS
heart	I-DS
failure	I-DS

1	O
.	O
02	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
66	O
)	O

0	O
.	O
936	O

1	O
.	O
10	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
93	O
)	O

0	O
.	O
739	O

1	O
.	O
67	O
(	O
0	O
.	O
79	O
–	O
3	O
.	O
55	O
)	O

0	O
.	O
180	O

0	O
.	O
96	O
(	O
0	O
.	O
70	O
–	O
1	O
.	O
32	O
)	O

0	O
.	O
806	O

Coronary	B-DS
heart	I-DS
disease	I-DS
or	O
myocardial	B-DS
infarction	I-DS

0	O
.	O
96	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
40	O
)	O

0	O
.	O
825	O

1	O
.	O
05	O
(	O
0	O
.	O
70	O
–	O
1	O
.	O
57	O
)	O

0	O
.	O
814	O

1	O
.	O
51	O
(	O
0	O
.	O
90	O
–	O
2	O
.	O
53	O
)	O

0	O
.	O
119	O

1	O
.	O
05	O
(	O
0	O
.	O
83	O
–	O
1	O
.	O
31	O
)	O

0	O
.	O
700	O

Atrial	B-DS
fibrillation	I-DS

1	O
.	O
11	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
63	O
)	O

0	O
.	O
595	O

1	O
.	O
62	O
(	O
1	O
.	O
09	O
–	O
2	O
.	O
40	O
)	O

0	O
.	O
017	O

0	O
.	O
70	O
(	O
0	O
.	O
36	O
–	O
1	O
.	O
35	O
)	O

0	O
.	O
290	O

1	O
.	O
16	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
46	O
)	O

0	O
.	O
227	O

Diabetes	B-DS

1	O
.	O
10	O
(	O
0	O
.	O
70	O
–	O
1	O
.	O
71	O
)	O

0	O
.	O
681	O

1	O
.	O
38	O
(	O
0	O
.	O
88	O
–	O
2	O
.	O
16	O
)	O

0	O
.	O
159	O

0	O
.	O
52	O
(	O
0	O
.	O
22	O
–	O
1	O
.	O
22	O
)	O

0	O
.	O
131	O

1	O
.	O
06	O
(	O
0	O
.	O
81	O
–	O
1	O
.	O
38	O
)	O

0	O
.	O
694	O

Hypertension	B-DS

0	O
.	O
86	O
(	O
0	O
.	O
62	O
–	O
1	O
.	O
19	O
)	O

0	O
.	O
370	O

0	O
.	O
89	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
26	O
)	O

0	O
.	O
513	O

1	O
.	O
12	O
(	O
0	O
.	O
72	O
–	O
1	O
.	O
77	O
)	O

0	O
.	O
612	O

0	O
.	O
92	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
12	O
)	O

0	O
.	O
400	O

Peripheral	B-DS
vascular	I-DS
disease	I-DS

1	O
.	O
62	O
(	O
0	O
.	O
77	O
–	O
3	O
.	O
39	O
)	O

0	O
.	O
205	O

1	O
.	O
19	O
(	O
0	O
.	O
48	O
–	O
2	O
.	O
98	O
)	O

0	O
.	O
708	O

0	O
.	O
59	O
(	O
0	O
.	O
08	O
–	O
4	O
.	O
29	O
)	O

0	O
.	O
601	O

1	O
.	O
22	O
(	O
0	O
.	O
73	O
–	O
2	O
.	O
03	O
)	O

0	O
.	O
444	O

Chronic	B-DS
kidney	I-DS
disease	I-DS

1	O
.	O
70	O
(	O
0	O
.	O
92	O
–	O
3	O
.	O
16	O
)	O

0	O
.	O
092	O

0	O
.	O
76	O
(	O
0	O
.	O
30	O
–	O
1	O
.	O
92	O
)	O

0	O
.	O
560	O

0	O
.	O
35	O
(	O
0	O
.	O
05	O
–	O
2	O
.	O
58	O
)	O

0	O
.	O
302	O

1	O
.	O
08	O
(	O
0	O
.	O
68	O
–	O
1	O
.	O
70	O
)	O

0	O
.	O
757	O

Chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS

1	O
.	O
32	O
(	O
0	O
.	O
75	O
–	O
2	O
.	O
34	O
)	O

0	O
.	O
341	O

0	O
.	O
57	O
(	O
0	O
.	O
23	O
–	O
1	O
.	O
41	O
)	O

0	O
.	O
224	O

0	O
.	O
92	O
(	O
0	O
.	O
33	O
–	O
2	O
.	O
54	O
)	O

0	O
.	O
867	O

0	O
.	O
87	O
(	O
0	O
.	O
58	O
–	O
1	O
.	O
31	O
)	O

0	O
.	O
511	O

Dementia	B-DS

0	O
.	O
73	O
(	O
0	O
.	O
37	O
–	O
1	O
.	O
42	O
)	O

0	O
.	O
355	O

0	O
.	O
59	O
(	O
0	O
.	O
24	O
–	O
1	O
.	O
49	O
)	O

0	O
.	O
267	O

0	O
.	O
70	O
(	O
0	O
.	O
16	O
–	O
3	O
.	O
01	O
)	O

0	O
.	O
635	O

0	O
.	O
70	O
(	O
0	O
.	O
43	O
–	O
1	O
.	O
14	O
)	O

0	O
.	O
152	O

Hyperlipidemia	B-DS

1	O
.	O
21	O
(	O
0	O
.	O
63	O
–	O
2	O
.	O
30	O
)	O

0	O
.	O
566	O

1	O
.	O
35	O
(	O
0	O
.	O
72	O
–	O
2	O
.	O
52	O
)	O

0	O
.	O
347	O

1	O
.	O
00	O
(	O
0	O
.	O
39	O
–	O
2	O
.	O
57	O
)	O

0	O
.	O
998	O

1	O
.	O
11	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
64	O
)	O

0	O
.	O
590	O

Cancer	B-DS

0	O
.	O
73	O
(	O
0	O
.	O
46	O
–	O
1	O
.	O
17	O
)	O

0	O
.	O
190	O

1	O
.	O
05	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
65	O
)	O

0	O
.	O
842	O

1	O
.	O
05	O
(	O
0	O
.	O
57	O
–	O
1	O
.	O
95	O
)	O

0	O
.	O
870	O

0	O
.	O
86	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
11	O
)	O

0	O
.	O
243	O

Table	O
6	O
indicates	O
the	O
number	O
of	O
events	O
over	O
the	O
total	O
number	O
of	O
person	O
years	O
follow	O
-	O
up	O
within	O
each	O
time	O
period	O
.	O

The	O
total	O
number	O
of	O
patients	O
in	O
each	O
analysis	O
from	O
0	O
to	O
1	O
to	O
3	O
–	O
5	O
years	O
decreased	O
due	O
to	O
the	O
exclusion	O
of	O
patients	O
who	O
had	O
either	O
suffered	O
an	O
event	O
or	O
died	O
in	O
previous	O
time	O
periods	O
to	O
reduce	O
the	O
impact	O
of	O
previous	O
events	O
on	O
later	O
analyses	O
and	O
allowing	O
clinicians	O
to	O
better	O
understand	O
factors	O
associated	O
with	O
the	O
falls	O
and	O
fracture	O
risk	O
based	O
on	O
patient	O
’	O
s	O
survival	O
.	O

Displaying	O
the	O
number	O
of	O
fall	O
and	O
fracture	O
events	O
,	O
over	O
the	O
total	O
number	O
of	O
person	O
years	O
during	O
each	O
time	O
period	O
.	O

Time	O
period	O

Falls	O
/	O
total	O
number	O

Fractures	O
/	O
total	O
number	O

0	O
–	O
365	O
days	O

336	O
/	O
7	O
,	O
090	O
.	O
10	O

234	O
/	O
7	O
,	O
130	O
.	O
22	O

366	O
–	O
1	O
,	O
095	O
days	O

379	O
/	O
13	O
,	O
451	O
.	O
20	O

207	O
/	O
13	O
,	O
853	O
.	O
89	O

1	O
,	O
096	O
–	O
1	O
,	O
825	O
days	O

216	O
/	O
12	O
,	O
870	O
.	O
42	O

116	O
/	O
13	O
,	O
526	O
.	O
41	O

0	O
–	O
3	O
,	O
650	O
days	O

1	O
,	O
138	O
/	O
64	O
,	O
447	O
.	O
99	O

666	O
/	O
67	O
,	O
726	O
.	O
70	O

Discussion	O

Our	O
study	O
has	O
found	O
several	O
factors	O
to	O
be	O
associated	O
with	O
poststroke	O
falls	O
and	O
fractures	O
.	O

The	O
identified	O
risk	O
factors	O
included	O
;	O
demographic	O
features	O
such	O
as	O
increasing	O
age	O
and	O
female	O
sex	O
,	O
and	O
comorbidities	O
such	O
as	O
a	O
previous	O
history	O
of	O
falls	O
and	O
atrial	B-DS
fibrillation	I-DS
,	O
which	O
were	O
associated	O
with	O
increased	O
risk	O
of	O
both	O
events	O
at	O
various	O
points	O
during	O
follow	O
-	O
up	O
,	O
additionally	O
,	O
chronic	B-DS
kidney	I-DS
disease	I-DS
and	O
hyperlipidemia	B-DS
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
falls	O
only	O
,	O
while	O
previous	O
stroke	B-DS
/	O
TIA	B-DS
increased	O
fracture	O
risk	O
.	O

Conversely	O
,	O
increasing	O
stroke	B-DS
severity	O
(	O
TACS	B-DS
)	O
and	O
premorbid	O
disability	O
depicted	O
by	O
prestroke	O
mRS	O
score	O
3	O
–	O
5	O
were	O
associated	O
with	O
decreased	O
risk	O
of	O
falls	O
and	O
fractures	O
,	O
while	O
hypertension	B-DS
and	O
cancer	B-DS
were	O
associated	O
with	O
decreased	O
risk	O
of	O
falls	O
only	O
.	O

It	O
can	O
also	O
be	O
seen	O
that	O
there	O
are	O
shared	O
risk	O
factors	O
with	O
non	O
-	O
stroke	B-DS
populations	O
.	O

Our	O
findings	O
,	O
therefore	O
,	O
are	O
in	O
-	O
keeping	O
with	O
previous	O
studies	O
where	O
female	O
sex	O
,	O
older	O
age	O
,	O
and	O
previous	O
falls	O
were	O
found	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
falls	O
and	O
fractures	O
after	O
stroke	B-DS
(	O
9	O
,	O
10	O
,	O
18	O
,	O
19	O
).	O

Furthermore	O
,	O
the	O
current	O
study	O
was	O
able	O
to	O
replicate	O
these	O
findings	O
while	O
addressing	O
some	O
of	O
the	O
limitations	O
inherent	O
to	O
some	O
previous	O
studies	O
,	O
such	O
as	O
short	O
follow	O
-	O
up	O
,	O
small	O
sample	O
sizes	O
,	O
or	O
limited	O
comorbidity	O
adjustment	O
.	O

Atrial	B-DS
fibrillation	I-DS
has	O
also	O
been	O
shown	O
to	O
be	O
associated	O
with	O
a	O
history	O
of	O
falls	O
in	O
a	O
study	O
examining	O
the	O
relationships	O
between	O
falls	O
history	O
,	O
atrial	B-DS
fibrillation	I-DS
,	O
and	O
mortality	O
(	O
20	O
)—	O
furthermore	O
,	O
it	O
has	O
also	O
been	O
linked	O
to	O
fracture	O
risk	O
in	O
a	O
large	O
population	O
-	O
based	O
study	O
with	O
robust	O
comorbid	O
adjustment	O
(	O
21	O
)	O
and	O
also	O
in	O
the	O
work	O
by	O
Kapral	O
et	O
al	O
.	O
investigating	O
fracture	O
risk	O
after	O
stroke	B-DS
(	O
19	O
).	O

Atrial	B-DS
fibrillation	I-DS
is	O
positively	O
associated	O
with	O
fractures	O
at	O
366	O
–	O
1	O
,	O
095	O
days	O
poststroke	O
(	O
HR	O
>	O
1	O
),	O
but	O
shows	O
a	O
HR	O
<	O
1	O
for	O
the	O
time	O
interval	O
1	O
,	O
096	O
–	O
1	O
,	O
825	O
days	O
poststroke	O
.	O

This	O
apparent	O
inconsistency	O
may	O
be	O
due	O
to	O
a	O
sample	O
size	O
issue	O
in	O
the	O
later	O
analyses	O
and	O
hence	O
resulting	O
in	O
a	O
type	O
II	O
error	O
.	O

Our	O
results	O
showed	O
that	O
chronic	B-DS
kidney	I-DS
disease	I-DS
was	O
a	O
risk	O
factor	O
for	O
falls	O
within	O
the	O
first	O
year	O
after	O
stroke	B-DS
discharge	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
bone	O
and	O
muscle	O
mass	O
among	O
other	O
factors	O
,	O
such	O
as	O
polypharmacy	O
,	O
leading	O
to	O
frail	O
patients	O
with	O
an	O
increased	O
risk	O
of	O
falls	O
,	O
as	O
shown	O
in	O
non	O
-	O
stroke	B-DS
populations	O
(	O
22	O
–	O
24	O
).	O

After	O
a	O
stroke	B-DS
,	O
there	O
is	O
also	O
muscle	O
wasting	O
(	O
25	O
),	O
which	O
further	O
contributes	O
toward	O
fall	O
risk	O
,	O
with	O
there	O
being	O
many	O
shared	O
risk	O
factors	O
between	O
stroke	B-DS
and	O
chronic	B-DS
kidney	I-DS
disease	I-DS
and	O
an	O
additional	O
association	O
with	O
chronic	B-DS
kidney	I-DS
disease	I-DS
patients	O
being	O
at	O
increased	O
risk	O
of	O
stroke	B-DS
(	O
26	O
).	O

As	O
with	O
people	O
with	O
atrial	B-DS
fibrillation	I-DS
,	O
with	O
reduced	O
sample	O
size	O
in	O
these	O
comorbid	O
groups	O
,	O
the	O
direction	O
of	O
effect	O
appeared	O
to	O
be	O
protective	O
beyond	O
year	O
1	O
in	O
people	O
with	O
chronic	B-DS
kidney	I-DS
disease	I-DS
.	O

Further	O
research	O
should	O
investigate	O
if	O
stroke	B-DS
patients	O
with	O
chronic	B-DS
kidney	I-DS
disease	I-DS
are	O
indeed	O
at	O
higher	O
risk	O
in	O
a	O
larger	O
sample	O
and	O
whether	O
this	O
is	O
due	O
to	O
these	O
combined	O
effects	O
leading	O
to	O
accelerated	O
loss	O
of	O
muscle	O
function	O
.	O

The	O
current	O
study	O
also	O
observed	O
a	O
history	O
of	O
previous	O
stroke	B-DS
/	O
TIA	B-DS
to	O
be	O
associated	O
with	O
increased	O
fracture	O
risk	O
over	O
follow	O
-	O
up	O
,	O
which	O
may	O
be	O
explained	O
by	O
the	O
reduced	O
bone	O
mass	O
of	O
stroke	B-DS
survivors	O
(	O
6	O
–	O
8	O
,	O
27	O
).	O

Female	O
sex	O
has	O
been	O
previously	O
linked	O
to	O
increased	O
risk	O
of	O
being	O
care	O
dependent	O
at	O
1	O
year	O
after	O
stroke	B-DS
as	O
they	O
are	O
older	O
and	O
suffer	O
from	O
more	O
geriatric	O
comorbidities	O
,	O
female	O
sex	O
could	O
,	O
therefore	O
,	O
be	O
seen	O
as	O
a	O
marker	O
of	O
such	O
factors	O
not	O
included	O
in	O
our	O
study	O
,	O
which	O
could	O
further	O
explain	O
the	O
associations	O
shown	O
(	O
28	O
).	O

Finally	O
,	O
the	O
current	O
study	O
found	O
that	O
hyperlipidemia	B-DS
was	O
associated	O
with	O
increased	O
risk	O
of	O
falls	O
.	O

This	O
may	O
be	O
related	O
to	O
the	O
use	O
of	O
statins	O
,	O
which	O
have	O
been	O
previously	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
falls	O
due	O
to	O
side	O
-	O
effects	O
such	O
as	O
muscle	O
pain	O
and	O
weakness	O
(	O
29	O
);	O
however	O
,	O
the	O
current	O
study	O
did	O
not	O
collect	O
data	O
regarding	O
statin	O
use	O
in	O
patients	O
and	O
so	O
this	O
association	O
remains	O
uncertain	O
.	O

Malignancy	O
and	O
associated	O
therapies	O
have	O
been	O
consistently	O
associated	O
with	O
bone	B-DS
loss	I-DS
(	O
30	O
,	O
31	O
).	O

Furthermore	O
,	O
the	O
side	O
effects	O
of	O
cancer	B-DS
treatment	O
,	O
such	O
as	O
chemotherapy	O
-	O
induced	O
peripheral	B-DS
neuropathy	I-DS
(	O
32	O
)	O
or	O
androgen	O
deprivation	O
therapy	O
(	O
e	O
.	O
g	O
.,	O
possible	O
loss	O
of	O
muscle	O
mass	O
)	O
(	O
33	O
,	O
34	O
)	O
may	O
lead	O
to	O
an	O
increased	O
risk	O
of	O
falls	O
.	O

However	O
,	O
the	O
current	O
study	O
found	O
an	O
association	O
between	O
malignancy	O
and	O
a	O
reduced	O
risk	O
of	O
poststroke	O
falls	O
and	O
no	O
association	O
with	O
fractures	O
,	O
after	O
adjusting	O
for	O
confounders	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
long	O
follow	O
-	O
up	O
of	O
our	O
study	O
and	O
the	O
possible	O
increased	O
mortality	O
of	O
patients	O
with	O
a	O
history	O
of	O
cancer	B-DS
during	O
the	O
short	O
-	O
term	O
follow	O
-	O
up	O
period	O
.	O

We	O
also	O
found	O
that	O
having	O
a	O
TACS	B-DS
or	O
mRS	O
score	O
of	O
3	O
–	O
5	O
reduced	O
fall	O
and	O
fracture	O
risk	O
.	O

We	O
acknowledge	O
that	O
the	O
mRS	O
score	O
was	O
not	O
created	O
to	O
be	O
applied	O
to	O
pre	O
-	O
stroke	B-DS
disability	O
.	O

However	O
,	O
we	O
,	O
and	O
others	O
,	O
have	O
shown	O
the	O
usefulness	O
of	O
mRS	O
on	O
prognosis	O
(	O
35	O
,	O
36	O
).	O

For	O
mRS	O
0	O
,	O
we	O
define	O
this	O
as	O
completely	O
normal	O
(	O
without	O
any	O
disability	O
).	O

We	O
have	O
used	O
the	O
current	O
classification	O
to	O
be	O
in	O
line	O
with	O
the	O
literature	O
(	O
where	O
mRS	O
greater	O
than	O
or	O
equal	O
to	O
3	O
is	O
regarded	O
as	O
an	O
indicator	O
of	O
severe	O
pre	O
-	O
stroke	B-DS
disability	O
).	O

These	O
negative	O
associations	O
could	O
,	O
therefore	O
,	O
similarly	O
be	O
explained	O
by	O
the	O
substantially	O
reduced	O
mobility	O
of	O
these	O
patients	O
or	O
possibly	O
increased	O
mortality	O
,	O
who	O
are	O
,	O
therefore	O
,	O
less	O
at	O
risk	O
of	O
an	O
event	O
.	O

Hypertension	B-DS
was	O
also	O
negatively	O
associated	O
with	O
falls	O
risk	O
from	O
1	O
to	O
3	O
years	O
.	O

A	O
previous	O
questionnaire	O
-	O
based	O
study	O
has	O
also	O
reported	O
an	O
observed	O
reduced	O
risk	O
of	O
falls	O
in	O
hypertensive	O
women	B-OG
,	O
and	O
it	O
has	O
also	O
been	O
suggested	O
that	O
high	B-DS
blood	I-DS
pressure	I-DS
is	O
associated	O
with	O
reduced	O
physical	O
and	O
cognitive	B-DS
decline	I-DS
,	O
which	O
may	O
account	O
for	O
this	O
decreased	O
risk	O
(	O
37	O
,	O
38	O
).	O

However	O
,	O
the	O
population	O
in	O
this	O
study	O
may	O
not	O
be	O
representative	O
as	O
this	O
concerns	O
the	O
oldest	O
old	O
.	O

Hypertension	B-DS
is	O
known	O
to	O
be	O
a	O
risk	O
factor	O
for	O
cognitive	B-DS
decline	I-DS
(	O
39	O
)	O
and	O
,	O
so	O
,	O
this	O
relationship	O
seen	O
also	O
remains	O
unclear	O
.	O

We	O
also	O
did	O
not	O
account	O
for	O
patient	O
use	O
of	O
antihypertensives	O
,	O
which	O
may	O
have	O
altered	O
the	O
relationship	O
observed	O
.	O

The	O
mechanisms	O
underlying	O
this	O
observed	O
association	O
,	O
therefore	O
,	O
remain	O
unclear	O
.	O

Falls	O
and	O
fractures	O
are	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
,	O
and	O
the	O
risk	O
factors	O
identified	O
in	O
the	O
current	O
study	O
can	O
help	O
predict	O
patients	O
at	O
risk	O
of	O
poststroke	O
falls	O
and	O
fractures	O
,	O
thereby	O
facilitating	O
the	O
implementation	O
of	O
preventative	O
strategies	O
,	O
such	O
as	O
exercises	O
,	O
medication	O
reviews	O
,	O
or	O
ensuring	O
safe	O
environments	O
to	O
improve	O
outcomes	O
(	O
40	O
).	O

Our	O
study	O
had	O
some	O
limitations	O
.	O

Bone	O
mineral	O
density	O
decreases	O
after	O
stroke	B-DS
;	O
however	O
,	O
we	O
did	O
not	O
have	O
these	O
data	O
and	O
were	O
,	O
therefore	O
,	O
unable	O
to	O
adjust	O
for	O
this	O
factor	O
.	O

We	O
did	O
not	O
examine	O
the	O
specific	O
type	O
of	O
fracture	O
risk	O
,	O
which	O
may	O
have	O
proved	O
important	O
;	O
however	O
,	O
even	O
with	O
our	O
large	O
sample	O
,	O
specific	O
fracture	O
type	O
analyses	O
may	O
have	O
reduced	O
the	O
study	O
power	O
.	O

Future	O
studies	O
are	O
required	O
to	O
better	O
understand	O
the	O
risk	O
factors	O
for	O
specific	O
fractures	O
with	O
higher	O
diseases	O
burden	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
indication	O
of	O
comorbid	O
disease	O
severity	O
,	O
which	O
could	O
benefit	O
the	O
validity	O
of	O
our	O
results	O
.	O

Selection	O
bias	O
may	O
be	O
a	O
significant	O
consideration	O
in	O
the	O
interpretation	O
of	O
the	O
analyses	O
,	O
due	O
to	O
the	O
exclusion	O
of	O
a	O
large	O
proportion	O
of	O
the	O
original	O
cohort	O
of	O
patients	O
.	O

However	O
,	O
it	O
should	O
be	O
noted	O
that	O
the	O
majority	O
of	O
exclusions	O
were	O
due	O
to	O
inpatient	O
deaths	O
(	O
and	O
,	O
therefore	O
,	O
inappropriate	O
for	O
our	O
outcome	O
of	O
post	O
-	O
discharge	O
events	O
)	O
or	O
repeat	O
admission	O
of	O
the	O
same	O
patient	O
during	O
follow	O
-	O
up	O
(	O
N	O
=	O
3	O
,	O
395	O
,	O
76	O
.	O
1	O
%	O
of	O
all	O
exclusions	O
),	O
as	O
detailed	O
(	O
Figure	O
S1	O
in	O
Supplementary	O
Material	O
).	O

Due	O
to	O
the	O
methods	O
of	O
data	O
collection	O
and	O
the	O
ascertainment	O
of	O
falls	O
and	O
fractures	O
based	O
on	O
ICD	O
-	O
10	O
codes	O
,	O
there	O
could	O
also	O
have	O
been	O
unreported	O
events	O
or	O
underestimation	O
of	O
their	O
true	O
prevalence	O
among	O
the	O
cohort	O
.	O

Milder	O
falls	O
are	O
likely	O
to	O
have	O
been	O
under	O
-	O
reported	O
and	O
thus	O
may	O
have	O
different	O
associated	O
factors	O
to	O
those	O
reported	O
here	O
,	O
where	O
events	O
reported	O
are	O
likely	O
to	O
be	O
more	O
major	O
.	O

However	O
,	O
any	O
underestimation	O
of	O
events	O
would	O
likely	O
only	O
have	O
attenuated	O
the	O
associations	O
seen	O
.	O

The	O
cohort	O
consisted	O
of	O
mainly	O
white	O
caucasians	O
and	O
whether	O
these	O
risk	O
factors	O
are	O
applicable	O
to	O
other	O
ethnic	O
groups	O
needs	O
to	O
be	O
tested	O
in	O
an	O
independent	O
dataset	O
with	O
ethnic	O
mix	O
.	O

Finally	O
,	O
as	O
an	O
observational	O
study	O
,	O
we	O
cannot	O
exclude	O
possibility	O
of	O
residual	O
confounding	O
.	O

Despite	O
these	O
limitations	O
,	O
our	O
study	O
had	O
strengths	O
in	O
the	O
robust	O
model	O
construction	O
,	O
and	O
we	O
were	O
able	O
to	O
control	O
for	O
multiple	O
confounders	O
and	O
comorbidities	O
over	O
a	O
long	O
duration	O
follow	O
-	O
up	O
of	O
10	O
years	O
and	O
our	O
discrete	O
period	O
analysis	O
also	O
allows	O
better	O
understanding	O
of	O
the	O
changing	O
risk	O
factor	O
profile	O
with	O
time	O
after	O
stroke	B-DS
.	O

In	O
addition	O
to	O
this	O
,	O
we	O
had	O
a	O
large	O
sample	O
size	O
,	O
which	O
has	O
allowed	O
us	O
to	O
address	O
some	O
limitations	O
in	O
the	O
previous	O
literature	O
.	O

Conclusion	O

In	O
summary	O
,	O
we	O
have	O
identified	O
and	O
confirmed	O
risk	O
factor	O
findings	O
of	O
previous	O
research	O
in	O
both	O
stroke	B-DS
and	O
non	O
-	O
stroke	B-DS
populations	O
,	O
such	O
as	O
age	O
,	O
female	O
sex	O
,	O
and	O
a	O
history	O
of	O
falls	O
,	O
in	O
a	O
manner	O
which	O
takes	O
into	O
account	O
discrete	O
follow	O
-	O
up	O
periods	O
.	O

The	O
results	O
from	O
this	O
study	O
imply	O
that	O
these	O
identified	O
factors	O
should	O
be	O
considered	O
in	O
stroke	B-DS
patients	O
to	O
identify	O
those	O
at	O
increased	O
risk	O
of	O
having	O
a	O
fall	O
or	O
fracture	O
post	O
-	O
discharge	O
.	O

Since	O
falls	O
and	O
fractures	O
after	O
stroke	B-DS
can	O
have	O
substantial	O
adverse	O
effects	O
,	O
identifying	O
at	O
-	O
risk	O
patients	O
early	O
on	O
may	O
allow	O
us	O
to	O
target	O
interventions	O
toward	O
these	O
patients	O
—	O
such	O
as	O
medication	O
reviews	O
and	O
ensuring	O
safe	O
mobility	O
—	O
and	O
thus	O
may	O
bring	O
substantial	O
benefit	O
to	O
patients	O
with	O
stroke	B-DS
.	O

Further	O
studies	O
are	O
required	O
to	O
examine	O
and	O
establish	O
the	O
relationship	O
between	O
reversible	O
factors	O
and	O
further	O
explore	O
the	O
role	O
of	O
preventative	O
measures	O
to	O
prevent	O
poststroke	O
falls	O
and	O
fractures	O
.	O

Data	O
Availability	O

Data	O
are	O
available	O
on	O
request	O
from	O
the	O
Norfolk	O
and	O
Norwich	O
University	O
Stroke	B-DS
and	O
TIA	B-DS
Register	O
Steering	O
Committee	O
.	O

Author	O
Contributions	O

PM	O
,	O
EF	O
,	O
and	O
RB	O
contributed	O
to	O
conception	O
and	O
design	O
of	O
the	O
study	O
.	O

The	O
dataset	O
used	O
in	O
this	O
study	O
is	O
maintained	O
by	O
our	O
colleagues	O
at	O
Norfolk	O
and	O
Norwich	O
(	O
JB	O
-	O
S	O
,	O
AC	O
,	O
AM	O
,	O
KB	O
,	O
and	O
JP	O
).	O

Statistical	O
analyses	O
were	O
performed	O
by	O
EF	O
and	O
supervised	O
by	O
RB	O
.	O

EF	O
wrote	O
the	O
first	O
draft	O
of	O
the	O
manuscript	O
,	O
which	O
was	O
redrafted	O
by	O
EF	O
,	O
RB	O
,	O
PM	O
,	O
and	O
JP	O
.	O

All	O
authors	O
contributed	O
to	O
,	O
read	O
,	O
and	O
approved	O
the	O
final	O
draft	O
of	O
the	O
manuscript	O
for	O
submission	O
.	O

PM	O
is	O
the	O
guarantor	O
.	O

Conflict	O
of	O
Interest	O
Statement	O

The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

